

## **NCCP DOSE BANDING TABLES**

### **DOSE BANDING FOR SYSTEMIC ANTICANCER THERAPY (SACT)**

**Version 4. August 2019**

Version	Date	Amendment		Approved By
1	03/06/2016	Version 1		Working Group
2	06/07/2017	<ul style="list-style-type: none"> <li>• Amendment to maximum variation range (%) calculation to keep in line with NCCP dose banding guidance documentation 2016</li> <li>• Expansion of existing tables: <ul style="list-style-type: none"> <li>- Carboplatin (v2)</li> <li>- Cetuximab (v2)</li> <li>- Cyclophosphamide IVB (v2)</li> <li>- Cyclophosphamide infusion (v2)</li> <li>- Docetaxel (v2)</li> <li>- Doxorubicin (v2)</li> <li>- Epirubicin (v2)</li> <li>- 5-Fluorouracil IVB (v2)</li> <li>- 5-Fluorouracil Infusors (v2)</li> <li>- Oxaliplatin (v2)</li> <li>- Rituximab (v2)</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Addition of new tables: <ul style="list-style-type: none"> <li>- Azacitidine (v1)</li> <li>- Bortezomib 2.5mg/ml (v1)</li> <li>- Bendamustine (v1)</li> <li>- Cisplatin (v1)</li> <li>- Cytarabine 100mg/ml (v1)</li> <li>- Etoposide (v1)</li> <li>- Methotrexate 100mg/ml (v1)</li> <li>- Pembrolizumab (v1)</li> <li>- Pemetrexed (v1)</li> <li>- Vinorelbine (v1)</li> </ul> </li> </ul>	Working Group
3	16/8/2018	<ul style="list-style-type: none"> <li>• Expansion of existing tables <ul style="list-style-type: none"> <li>- 5-Fluorouracil Infusors (including note regarding SV2.5 infusors) (v3)</li> <li>- Gemcitabine 38mg/ml (v3)</li> <li>- Gemcitabine 40mg/ml (v3)</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Addition of new tables <ul style="list-style-type: none"> <li>- Daratumumab (v1)</li> <li>- Dacarbazine (v1)</li> </ul> </li> </ul>	Working group
4	23/08/2019	<ul style="list-style-type: none"> <li>• Removal of pembrolizumab (Now flat dosing)</li> <li>• Expansion of existing tables <ul style="list-style-type: none"> <li>- Carboplatin (v3)</li> <li>- Gemcitabine 38mg/ml (v4)</li> <li>- Gemcitabine 40mg/ml (v4)</li> <li>- Oxaliplatin (v3)</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>• Addition of new tables: <ul style="list-style-type: none"> <li>- Mitomycin (v1)</li> <li>- Bleomycin (v1)</li> <li>- Carfilzomib (v1)</li> <li>- Ipilimumab (v1)</li> <li>- Nab-Paclitaxel (v1)</li> <li>- Trastuzumab emtansine (v1)</li> </ul> </li> </ul>	Working group

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## Table of Contents

<b>NCCP DOSE BANDING TABLES</b> .....	<b>1</b>
<b>Table of Contents</b> .....	<b>3</b>
Introduction.....	5
<b>DOSE BANDING TABLES – SYRINGES FOR SUBCUTANEOUS INJECTION:</b> .....	<b>6</b>
AZACITIDINE SUBCUTANEOUS INJECTION.....	6
BORTEZOMIB SUBCUTANEOUS INJECTION .....	7
<b>DOSE BANDING TABLES – SYRINGES FOR BOLUS INJECTION:</b> .....	<b>8</b>
BLEOMYCIN SYRINGES.....	8
CYCLOPHOSPHAMIDE SYRINGES.....	9
DOXORUBICIN SYRINGES.....	10
EPIRUBICIN SYRINGES.....	11
5-FLUOROURACIL SYRINGES.....	12
MITOMYCIN SYRINGES.....	13
<b>DOSE BANDING TABLES – INFUSIONS FOR INTRAVENOUS ADMINISTRATION:</b> .....	<b>14</b>
BENDAMUSTINE IV INFUSION.....	14
CARFILZOMIB IV INFUSION .....	15
CARBOPLATIN IV INFUSION.....	16
CISPLATIN IV INFUSION.....	18
CYCLOPHOSPHAMIDE IV INFUSION.....	19
CYTARABINE IV INFUSION .....	21
DACARBAZINE INFUSION .....	23
DOCETAXEL IV INFUSION.....	24
ETOPOSIDE IV INFUSION .....	25
5-FLUOROURACIL IV INFUSION.....	26
5-FLUOROURACIL INFUSORS .....	28
40mg/ml GEMCITABINE IV INFUSION.....	29
38mg/ml GEMCITABINE IV INFUSION.....	30
IRINOTECAN IV INFUSION .....	31
METHOTREXATE IV INFUSION.....	32
NAB-PACLITAXEL IV INFUSION .....	35

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

OXALIPLATIN IV INFUSION .....	36
PACLITAXEL IV INFUSION.....	37
PEMETREXED IV INFUSION.....	38
TRASTUZUMAB EMTANSINE IV INFUSION.....	39
VINORELBINE IV INFUSION .....	40
<b>DOSE BANDING TABLES – MONOCLONALS FOR INTRAVENOUS INFUSION.....</b>	<b>41</b>
MONOCLONALS - BEVACIZUMAB IV INFUSION.....	41
MONOCLONALS – CETUXIMAB IV INFUSION.....	43
MONOCLONALS- DARATUMUMAB INFUSION.....	44
MONOCLONALS – IPILIMUMAB IV INFUSION .....	45
MONOCLONALS – RITUXIMAB IV INFUSION .....	46
MONOCLONALS - TRASTUZUMAB IV INFUSION .....	47
<b>DOSE BANDING TABLES – ORAL ANTI-CANCER MEDICATIONS:.....</b>	<b>48</b>
CAPECITABINE .....	48

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## Introduction

This document contains the NCCP national dose banding tables.

The dose band tables have been developed in line with the NCCP Dose Banding Guidance document recommendations for dose banding calculations and have been agreed with ISMO and IHS. All dose bands contained in these tables are subject to local implementation and as deemed relevant to local practice.

The dose bands have been developed to cover the majority of potential doses to be given to patients. However, it is not expected that all these doses will be used commonly and that in fact, each site should identify the most likely doses applicable to their practice. The extreme ends of the dose band table can be applied to patient specific doses as and when they arise.

Each dose banding table has a version number which will be updated if modifications to the table are required or if a new table has been developed.

Dose rounding has been applied to some of these tables as opposed to dose banding. This is in order to facilitate the nearest measurable volume.

Dose bands exceeding the targeted +/-5% variation from prescribed dose are highlighted in red.

## Review and Feedback

The dose band tables will be reviewed and updated as required. Please send any comments to [oncologydrugs@cancercontrol.ie](mailto:oncologydrugs@cancercontrol.ie)

If you wish to suggest drugs suitable for dose banding, please outline the drug and the suggested dose bands and send to [oncologydrugs@cancercontrol.ie](mailto:oncologydrugs@cancercontrol.ie)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## DOSE BANDING TABLES – SYRINGES FOR SUBCUTANEOUS INJECTION:

### AZACITIDINE SUBCUTANEOUS INJECTION (Version 1)

The dose bands used in this table are constructed based on a 25mg/ml concentration of azacitidine

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
73 - 77	<b>75</b>	2.60% (Upr)" , -2.74% (Lwr)	2mg (Upr), -2mg (Lwr)
78 - 82	<b>80</b>	2.44% (Upr)" , -2.56% (Lwr)	2mg (Upr), -2mg (Lwr)
83 - 87	<b>85</b>	2.30% (Upr)" , -2.41% (Lwr)	2mg (Upr), -2mg (Lwr)
88 - 92	<b>90</b>	2.17% (Upr)" , -2.27% (Lwr)	2mg (Upr), -2mg (Lwr)
93 - 97	<b>95</b>	2.06% (Upr)" , -2.15% (Lwr)	2mg (Upr), -2mg (Lwr)
98 - 105	<b>100</b>	4.76% (Upr)" , -2.04% (Lwr)	5mg (Upr), -2mg (Lwr)
106 - 115	<b>110</b>	4.35% (Upr)" , -3.77% (Lwr)	5mg (Upr), -4mg (Lwr)
116 - 125	<b>120</b>	4.00% (Upr)" , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)
126 - 135	<b>130</b>	3.70% (Upr)" , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)
136 - 145	<b>140</b>	3.45% (Upr)" , -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)
146 - 157	<b>150</b>	4.46% (Upr)" , -2.74% (Lwr)	7mg (Upr), -4mg (Lwr)
158 - 172	<b>165</b>	4.07% (Upr)" , -4.43% (Lwr)	7mg (Upr), -7mg (Lwr)
173 - 189	<b>180</b>	4.76% (Upr)" , -4.05% (Lwr)	9mg (Upr), -7mg (Lwr)
190 - 212	<b>200</b>	5.66% (Upr)" , -5.26% (Lwr)	12mg (Upr), -10mg (Lwr)
213 - 237	<b>225</b>	5.06% (Upr)" , -5.63% (Lwr)	12mg (Upr), -12mg (Lwr)
238 - 262	<b>250</b>	4.58% (Upr)" , -5.04% (Lwr)	12mg (Upr), -12mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## BORTEZOMIB SUBCUTANEOUS INJECTION (Version 1)

The dose bands used in this table are constructed based on a 2.5mg/ml concentration of bortezomib

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
1.43 - 1.62	<b>1.5</b>	7.41% (Upr)" , -4.90% (Lwr)	0.12mg (Upr), -0.07mg (Lwr)
1.63 - 1.87	<b>1.75</b>	6.42% (Upr)" , -7.36% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
1.88 - 2.12	<b>2</b>	5.66% (Upr)" , -6.38% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
2.13 - 2.37	<b>2.25</b>	5.06% (Upr)" , -5.63% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
2.38 - 2.62	<b>2.5</b>	4.58% (Upr)" , -5.04% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
2.63 - 2.87	<b>2.75</b>	4.18% (Upr)" , -4.56% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
2.88 - 3.12	<b>3</b>	3.85% (Upr)" , -4.17% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
3.13 - 3.37	<b>3.25</b>	3.56% (Upr)" , -3.83% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
3.38 - 3.62	<b>3.5</b>	3.31% (Upr)" , -3.55% (Lwr)	0.12mg (Upr), -0.12mg (Lwr)
3.63 - 3.9	<b>3.75</b>	3.85% (Upr)" , -3.31% (Lwr)	0.15mg (Upr), -0.12mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## DOSE BANDING TABLES – SYRINGES FOR BOLUS INJECTION:

### BLEOMYCIN SYRINGES (Version 1)

The dose bands used in this table are constructed based on a 3mg/ml (3,000IU/ml) concentration of bleomycin.

(Please note bleomycin dosing may be referred to in International units (IU) or in mg. 1,000 international units = 1mg.)

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Banded Dose (International Units)	Maximum variation range (%)	Maximum variation range (mg)
5.80 - 6.29	<b>6</b>	6000	4.61% (Upr)" , -3.45% (Lwr)	0.29mg (Upr), -0.20mg (Lwr)
6.30 - 6.89	<b>6.6</b>	6600	4.21% (Upr)" , -4.76% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
6.90 - 7.49	<b>7.2</b>	7200	3.87% (Upr)" , -4.35% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
7.50 - 8.09	<b>7.8</b>	7800	3.58% (Upr)" , -4.00% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
8.10 - 8.69	<b>8.4</b>	8400	3.34% (Upr)" , -3.70% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
8.70 - 9.29	<b>9</b>	9000	3.12% (Upr)" , -3.45% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
9.30 - 9.89	<b>9.6</b>	9600	2.93% (Upr)" , -3.23% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
9.90 - 10.49	<b>10.2</b>	10200	2.76% (Upr)" , -3.03% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
10.50 - 11.09	<b>10.8</b>	10800	2.61% (Upr)" , -2.86% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
11.10 - 11.69	<b>11.4</b>	11400	2.48% (Upr)" , -2.70% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
11.70 - 12.58	<b>12</b>	12000	4.61% (Upr)" , -2.56% (Lwr)	0.58mg (Upr), -0.30mg (Lwr)
12.59 - 13.78	<b>13.2</b>	13200	4.21% (Upr)" , -4.85% (Lwr)	0.58mg (Upr), -0.61mg (Lwr)
13.79 - 14.98	<b>14.4</b>	14400	3.87% (Upr)" , -4.42% (Lwr)	0.58mg (Upr), -0.61mg (Lwr)
14.99 - 16.18	<b>15.6</b>	15600	3.58% (Upr)" , -4.07% (Lwr)	0.58mg (Upr), -0.61mg (Lwr)
16.19 - 17.38	<b>16.8</b>	16800	3.34% (Upr)" , -3.77% (Lwr)	0.58mg (Upr), -0.61mg (Lwr)
17.39 - 18.58	<b>18</b>	18000	3.12% (Upr)" , -3.51% (Lwr)	0.58mg (Upr), -0.61mg (Lwr)
18.59 - 19.78	<b>19.2</b>	19200	2.93% (Upr)" , -3.28% (Lwr)	0.58mg (Upr), -0.61mg (Lwr)
19.79 - 21.27	<b>20.4</b>	20400	4.09% (Upr)" , -3.08% (Lwr)	0.87mg (Upr), -0.61mg (Lwr)
21.28 - 23.07	<b>22.2</b>	22200	3.77% (Upr)" , -4.32% (Lwr)	0.87mg (Upr), -0.92mg (Lwr)
23.08 - 24.87	<b>24</b>	24000	3.50% (Upr)" , -3.99% (Lwr)	0.87mg (Upr), -0.92mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		



## CYCLOPHOSPHAMIDE SYRINGES (Version 2)

The dose bands used in this table are constructed based on a 20mg/ml concentration of cyclophosphamide

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)	Suggested Syringes
380 - 429	<b>400</b>	6.76% (Upr)", -5.26% (Lwr)	29mg (Upr), -20mg (Lwr)	400mg
430 - 479	<b>460</b>	3.97% (Upr)", -6.98% (Lwr)	19mg (Upr), -30mg (Lwr)	200mg, 260mg
480 - 529	<b>500</b>	5.48% (Upr)", -4.17% (Lwr)	29mg (Upr), -20mg (Lwr)	500mg
530 - 579	<b>560</b>	3.28% (Upr)", -5.66% (Lwr)	19mg (Upr), -30mg (Lwr)	300mg, 260mg
580 - 629	<b>600</b>	4.61% (Upr)", -3.45% (Lwr)	29mg (Upr), -20mg (Lwr)	300mg x 2
630 - 679	<b>660</b>	2.80% (Upr)", -4.76% (Lwr)	19mg (Upr), -30mg (Lwr)	400mg, 260mg
680 - 729	<b>700</b>	3.98% (Upr)", -2.94% (Lwr)	29mg (Upr), -20mg (Lwr)	400mg, 300mg
730 - 779	<b>760</b>	2.44% (Upr)", -4.11% (Lwr)	19mg (Upr), -30mg (Lwr)	500mg, 260mg
780 - 829	<b>800</b>	3.50% (Upr)", -2.56% (Lwr)	29mg (Upr), -20mg (Lwr)	400mg x 2
830 - 879	<b>860</b>	2.16% (Upr)", -3.61% (Lwr)	19mg (Upr), -30mg (Lwr)	400mg, 200mg, 260mg
880 - 929	<b>900</b>	3.12% (Upr)", -2.27% (Lwr)	29mg (Upr), -20mg (Lwr)	500mg, 400mg
930 - 979	<b>960</b>	1.94% (Upr)", -3.23% (Lwr)	19mg (Upr), -30mg (Lwr)	500mg, 200mg, 260mg
980 - 1050	<b>1000</b>	4.76% (Upr)", -2.04% (Lwr)	50mg (Upr), -20mg (Lwr)	1000mg
1051 - 1150	<b>1100</b>	4.35% (Upr)", -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)	500mg, 400mg, 200mg
1151 - 1250	<b>1200</b>	4.00% (Upr)", -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 200mg
1251 - 1350	<b>1300</b>	3.70% (Upr)", -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 300mg
1351 - 1450	<b>1400</b>	3.45% (Upr)", -3.63% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 400mg
1451 - 1550	<b>1500</b>	3.23% (Upr)", -3.38% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 500mg
1551 - 1650	<b>1600</b>	3.03% (Upr)", -3.16% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 300mg, 300mg
1651 - 1750	<b>1700</b>	2.86% (Upr)", -2.97% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 300mg, 400mg
1751 - 1850	<b>1800</b>	2.70% (Upr)", -2.80% (Lwr)	50mg (Upr), -49mg (Lwr)	1000ng, 400mg, 400mg
1851 - 1950	<b>1900</b>	2.56% (Upr)", -2.65% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 500mg, 400mg

Suggested Stock Syringe Sizes: 200mg, 260mg, 300mg, 400mg, 500mg, 1000mg

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## DOXORUBICIN SYRINGES (Version 2)

The dose bands used in this table are constructed based on a 2mg/ml concentration of doxorubicin

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)	Suggested Syringes
31 - 33	<b>32</b>	3.03% (Upr)" , -3.23% (Lwr)	1mg (Upr), -1mg (Lwr)	
34 - 37	<b>36</b>	2.70% (Upr)" , -5.88% (Lwr)	1mg (Upr), -2mg (Lwr)	
38 - 42	<b>40</b>	4.76% (Upr)" , -5.26% (Lwr)	2mg (Upr), -2mg (Lwr)	40mg
43 - 48	<b>46</b>	4.17% (Upr)" , -6.98% (Lwr)	2mg (Upr), -3mg (Lwr)	20mg, 26mg
49 - 53	<b>50</b>	5.66% (Upr)" , -2.04% (Lwr)	3mg (Upr), -1mg (Lwr)	50mg
54 - 58	<b>56</b>	3.45% (Upr)" , -3.70% (Lwr)	2mg (Upr), -2mg (Lwr)	30mg, 26mg
59 - 63	<b>60</b>	4.76% (Upr)" , -1.69% (Lwr)	3mg (Upr), -1mg (Lwr)	30mg x 2
64 - 68	<b>66</b>	2.94% (Upr)" , -3.13% (Lwr)	2mg (Upr), -2mg (Lwr)	40mg, 26mg
69 - 73	<b>70</b>	4.11% (Upr)" , -1.45% (Lwr)	3mg (Upr), -1mg (Lwr)	40mg, 30mg
74 - 78	<b>76</b>	2.56% (Upr)" , -2.70% (Lwr)	2mg (Upr), -2mg (Lwr)	50mg, 26mg
79 - 83	<b>80</b>	3.61% (Upr)" , -1.27% (Lwr)	3mg (Upr), -1mg (Lwr)	50mg, 30mg
84 - 88	<b>86</b>	2.27% (Upr)" , -2.38% (Lwr)	2mg (Upr), -2mg (Lwr)	40mg, 20mg, 26mg
89 - 93	<b>90</b>	3.23% (Upr)" , -1.12% (Lwr)	3mg (Upr), -1mg (Lwr)	40mg, 50mg
94 - 97	<b>96</b>	1.03% (Upr)" , -2.13% (Lwr)	1mg (Upr), -2mg (Lwr)	50mg, 20mg, 26mg
98 - 105	<b>100</b>	4.76% (Upr)" , -2.04% (Lwr)	5mg (Upr), -2mg (Lwr)	100mg
106 - 115	<b>110</b>	4.35% (Upr)" , -3.77% (Lwr)	5mg (Upr), -4mg (Lwr)	50mg, 40mg, 20mg
116 - 125	<b>120</b>	4.00% (Upr)" , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 20mg
126 - 135	<b>130</b>	3.70% (Upr)" , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 30mg
136 - 145	<b>140</b>	3.45% (Upr)" , -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 40mg
146 - 155	<b>150</b>	3.23% (Upr)" , -2.74% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 50mg
156 - 165	<b>160</b>	3.03% (Upr)" , -2.56% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 30mg x 2
166 - 175	<b>170</b>	2.86% (Upr)" , -2.41% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 40mg, 30mg
176 - 185	<b>180</b>	2.70% (Upr)" , -2.27% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 400mg x 2
186 - 195	<b>190</b>	2.56% (Upr)" , -2.15% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 50mg, 40mg
196 - 210	<b>200</b>	4.76% (Upr)" , -2.04% (Lwr)	10mg (Upr), -4mg (Lwr)	100mg x 2
211 - 230	<b>220</b>	4.35% (Upr)" , -4.27% (Lwr)	10mg (Upr), -9mg (Lwr)	100mg x 2, 20mg x 1
231 - 250	<b>240</b>	4.00% (Upr)" , -3.90% (Lwr)	10mg (Upr), -9mg (Lwr)	100mg x 2, 40mg x 1

Suggested Stock Syringe Sizes: 20mg, 26mg, 30mg, 40mg, 50mg, 100mg

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## EPIRUBICIN SYRINGES (Version 2)

The dose bands used in this table are constructed based on a 2mg/ml concentration of epirubicin

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)	Suggested Syringes
30 - 33	<b>32</b>	3.03% (Upr) , -6.67% (Lwr)	1mg (Upr), -2mg (Lwr)	
34 - 37	<b>36</b>	2.70% (Upr) , -5.88% (Lwr)	1mg (Upr), -2mg (Lwr)	
38 - 42	<b>40</b>	4.76% (Upr) , -5.26% (Lwr)	2mg (Upr), -2mg (Lwr)	40mg
43 - 47	<b>46</b>	2.13% (Upr) , -6.98% (Lwr)	1mg (Upr), -3mg (Lwr)	20mg, 26mg
48 - 52	<b>50</b>	3.85% (Upr) , -4.17% (Lwr)	2mg (Upr), -2mg (Lwr)	50mg
53 - 57	<b>56</b>	1.75% (Upr) , -5.66% (Lwr)	1mg (Upr), -3mg (Lwr)	30mg, 26mg
58 - 62	<b>60</b>	3.23% (Upr) , -3.45% (Lwr)	2mg (Upr), -2mg (Lwr)	30mg x 2
63 - 67	<b>66</b>	1.49% (Upr) , -4.76% (Lwr)	1mg (Upr), -3mg (Lwr)	40mg, 26mg
68 - 72	<b>70</b>	2.78% (Upr) , -2.94% (Lwr)	2mg (Upr), -2mg (Lwr)	40mg, 30mg
73 - 77	<b>76</b>	1.30% (Upr) , -4.11% (Lwr)	1mg (Upr), -3mg (Lwr)	50mg, 26mg
78 - 82	<b>80</b>	2.44% (Upr) , -2.56% (Lwr)	2mg (Upr), -2mg (Lwr)	50mg, 30mg
83 - 87	<b>86</b>	1.15% (Upr) , -3.61% (Lwr)	1mg (Upr), -3mg (Lwr)	40mg, 20mg, 26mg
88 - 92	<b>90</b>	2.17% (Upr) , -2.27% (Lwr)	2mg (Upr), -2mg (Lwr)	40mg, 50mg
93 - 97	<b>96</b>	1.03% (Upr) , -3.23% (Lwr)	1mg (Upr), -3mg (Lwr)	50mg, 20mg, 26mg
98 - 105	<b>100</b>	4.76% (Upr) , -2.04% (Lwr)	5mg (Upr), -2mg (Lwr)	100mg
106 - 115	<b>110</b>	4.35% (Upr) , -3.77% (Lwr)	5mg (Upr), -4mg (Lwr)	50mg, 40mg, 20mg
116 - 125	<b>120</b>	4.00% (Upr) , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 20mg
126 - 135	<b>130</b>	3.70% (Upr) , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 30mg
136 - 145	<b>140</b>	3.45% (Upr) , -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 40mg
146 - 155	<b>150</b>	3.23% (Upr) , -2.74% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 50mg
156 - 165	<b>160</b>	3.03% (Upr) , -2.56% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 30mg x 2
166 - 175	<b>170</b>	2.86% (Upr) , -2.41% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 40mg, 30mg
176 - 185	<b>180</b>	2.70% (Upr) , -2.27% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 40mg x 2
186 - 195	<b>190</b>	2.56% (Upr) , -2.15% (Lwr)	5mg (Upr), -4mg (Lwr)	100mg, 50mg, 40mg
196 - 210	<b>200</b>	4.76% (Upr) , -2.04% (Lwr)	10mg (Upr), -4mg (Lwr)	100mg x 2
211 - 230	<b>220</b>	4.35% (Upr) , -4.27% (Lwr)	10mg (Upr), -9mg (Lwr)	100mg x 2, 20mg x 1
231 - 250	<b>240</b>	4.00% (Upr) , -3.90% (Lwr)	10mg (Upr), -9mg (Lwr)	100mg x 2, 40mg x 1

Suggested Stock Syringe Sizes: 20mg, 26mg, 30mg, 40mg, 50mg, 100mg

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## 5-FLUOROURACIL SYRINGES (Version 2)

The dose bands used in this table are constructed based on a 25mg/ml concentration of 5-fluorouracil

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)	Suggested Syringes
238 - 262	<b>250</b>	4.58% (Upr)" , -5.04% (Lwr)	12mg (Upr), -12mg (Lwr)	250mg
263 - 287	<b>275</b>	4.18% (Upr)" , -4.56% (Lwr)	12mg (Upr), -12mg (Lwr)	
288 - 312	<b>300</b>	3.85% (Upr)" , -4.17% (Lwr)	12mg (Upr), -12mg (Lwr)	300mg
313 - 337	<b>325</b>	3.56% (Upr)" , -3.83% (Lwr)	12mg (Upr), -12mg (Lwr)	
338 - 362	<b>350</b>	3.31% (Upr)" , -3.55% (Lwr)	12mg (Upr), -12mg (Lwr)	
363 - 387	<b>375</b>	3.10% (Upr)" , -3.31% (Lwr)	12mg (Upr), -12mg (Lwr)	
388 - 424	<b>400</b>	5.66% (Upr)" , -3.09% (Lwr)	24mg (Upr), -12mg (Lwr)	400mg
425 - 474	<b>450</b>	5.06% (Upr)" , -5.88% (Lwr)	24mg (Upr), -25mg (Lwr)	
475 - 525	<b>500</b>	4.76% (Upr)" , -5.26% (Lwr)	25mg (Upr), -25mg (Lwr)	500mg
526 - 575	<b>550</b>	4.35% (Upr)" , -4.56% (Lwr)	25mg (Upr), -24mg (Lwr)	300mg, 250mg
576 - 625	<b>600</b>	4.00% (Upr)" , -4.17% (Lwr)	25mg (Upr), -24mg (Lwr)	600mg
626 - 675	<b>650</b>	3.70% (Upr)" , -3.83% (Lwr)	25mg (Upr), -24mg (Lwr)	400mg, 250mg
676 - 725	<b>700</b>	3.45% (Upr)" , -3.55% (Lwr)	25mg (Upr), -24mg (Lwr)	400mg, 300mg
726 - 775	<b>750</b>	3.23% (Upr)" , -3.31% (Lwr)	25mg (Upr), -24mg (Lwr)	500mg, 250mg
776 - 825	<b>800</b>	3.03% (Upr)" , -3.09% (Lwr)	25mg (Upr), -24mg (Lwr)	400mg x 2
826 - 875	<b>850</b>	2.86% (Upr)" , -2.91% (Lwr)	25mg (Upr), -24mg (Lwr)	600mg, 250mg
876 - 925	<b>900</b>	2.70% (Upr)" , -2.74% (Lwr)	25mg (Upr), -24mg (Lwr)	500mg, 400mg
926 - 975	<b>950</b>	2.56% (Upr)" , -2.59% (Lwr)	25mg (Upr), -24mg (Lwr)	400mg, 300mg, 250mg
976 - 1050	<b>1000</b>	4.76% (Upr)" , -2.46% (Lwr)	50mg (Upr), -24mg (Lwr)	1000mg
1051 - 1150	<b>1100</b>	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)	500mg, 400mg, 200mg
1151 - 1250	<b>1200</b>	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 200mg
1251 - 1350	<b>1300</b>	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 300mg
1351 - 1450	<b>1400</b>	3.45% (Upr)" , -3.63% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 400mg
1451 - 1550	<b>1500</b>	3.23% (Upr)" , -3.38% (Lwr)	50mg (Upr), -49mg (Lwr)	1000mg, 500mg

Suggested Stock Syringe Sizes: 250mg, 300mg, 400mg, 500mg, 600mg, 1000mg

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## MITOMYCIN SYRINGES (Version 1)

The dose bands used in this table are constructed based on a 1mg/ml concentration of mitomycin

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
2.90 - 3.19	<b>3</b>	5.96% (Upr)", -3.45% (Lwr)	0.19mg (Upr), -0.1mg (Lwr)
3.20 - 3.59	<b>3.4</b>	5.29% (Upr)", -6.25% (Lwr)	0.19mg (Upr), -0.2mg (Lwr)
3.60 - 3.99	<b>3.8</b>	4.76% (Upr)", -5.56% (Lwr)	0.19mg (Upr), -0.2mg (Lwr)
4.00 - 4.39	<b>4.2</b>	4.33% (Upr)", -5.00% (Lwr)	0.19mg (Upr), -0.2mg (Lwr)
4.40 - 4.79	<b>4.6</b>	3.97% (Upr)", -4.55% (Lwr)	0.19mg (Upr), -0.20mg (Lwr)
4.80 - 5.19	<b>5</b>	3.66% (Upr)", -4.17% (Lwr)	0.19mg (Upr), -0.2mg (Lwr)
5.20 - 5.59	<b>5.4</b>	3.40% (Upr)", -3.85% (Lwr)	0.19mg (Upr), -0.2mg (Lwr)
5.60 - 6.09	<b>5.8</b>	4.76% (Upr)", -3.57% (Lwr)	0.29mg (Upr), -0.2mg (Lwr)
6.10 - 6.69	<b>6.4</b>	4.33% (Upr)", -4.92% (Lwr)	0.29mg (Upr), -0.30mg (Lwr)
6.70 - 7.29	<b>7</b>	3.98% (Upr)", -4.48% (Lwr)	0.29mg (Upr), -0.3mg (Lwr)
7.30 - 7.99	<b>7.6</b>	4.88% (Upr)", -4.11% (Lwr)	0.39mg (Upr), -0.30mg (Lwr)
8.00 - 8.79	<b>8.4</b>	4.44% (Upr)", -5.00% (Lwr)	0.39mg (Upr), -0.4mg (Lwr)
8.80 - 9.59	<b>9.2</b>	4.07% (Upr)", -4.55% (Lwr)	0.39mg (Upr), -0.40mg (Lwr)
9.60 - 10.50	<b>10</b>	4.76% (Upr)", -4.17% (Lwr)	0.5mg (Upr), -0.4mg (Lwr)
10.51 - 11.50	<b>11</b>	4.35% (Upr)", -4.66% (Lwr)	0.5mg (Upr), -0.49mg (Lwr)
11.51 - 12.50	<b>12</b>	4.00% (Upr)", -4.26% (Lwr)	0.5mg (Upr), -0.49mg (Lwr)
12.51 - 13.50	<b>13</b>	3.70% (Upr)", -3.92% (Lwr)	0.5mg (Upr), -0.49mg (Lwr)
13.51 - 14.50	<b>14</b>	3.45% (Upr)", -3.63% (Lwr)	0.5mg (Upr), -0.49mg (Lwr)
14.51 - 15.50	<b>15</b>	3.23% (Upr)", -3.38% (Lwr)	0.5mg (Upr), -0.49mg (Lwr)
15.51 - 16.50	<b>16</b>	3.03% (Upr)", -3.16% (Lwr)	0.5mg (Upr), -0.49mg (Lwr)
16.51 - 17.50	<b>17</b>	2.86% (Upr)", -2.97% (Lwr)	0.50mg (Upr), -0.49mg (Lwr)
17.51 - 18.99	<b>18</b>	5.21% (Upr)", -2.80% (Lwr)	0.99mg (Upr), -0.49mg (Lwr)
19.00 - 21.00	<b>20</b>	4.76% (Upr)", -5.26% (Lwr)	1mg (Upr), -1mg (Lwr)
21.01 - 23.00	<b>22</b>	4.35% (Upr)", -4.71% (Lwr)	1mg (Upr), -0.99mg (Lwr)
23.01 - 25.00	<b>24</b>	4.00% (Upr)", -4.30% (Lwr)	1mg (Upr), -0.99mg (Lwr)
25.01 - 27.00	<b>26</b>	3.70% (Upr)", -3.96% (Lwr)	1mg (Upr), -0.99mg (Lwr)
27.01 - 29.00	<b>28</b>	3.45% (Upr)", -3.67% (Lwr)	1mg (Upr), -0.99mg (Lwr)
29.01 - 31.00	<b>30</b>	3.23% (Upr)", -3.41% (Lwr)	1mg (Upr), -0.99mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## DOSE BANDING TABLES – INFUSIONS FOR INTRAVENOUS ADMINISTRATION:

### BENDAMUSTINE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 2.5mg/ml concentration of bendamustine

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
73 - 77	<b>75</b>	2.60% (Upr)" , -2.74% (Lwr)	2mg (Upr), -2mg (Lwr)
78 - 82	<b>80</b>	2.44% (Upr)" , -2.56% (Lwr)	2mg (Upr), -2mg (Lwr)
83 - 87	<b>85</b>	2.30% (Upr)" , -2.41% (Lwr)	2mg (Upr), -2mg (Lwr)
88 - 92	<b>90</b>	2.17% (Upr)" , -2.27% (Lwr)	2mg (Upr), -2mg (Lwr)
93 - 97	<b>95</b>	2.06% (Upr)" , -2.15% (Lwr)	2mg (Upr), -2mg (Lwr)
98 - 105	<b>100</b>	4.76% (Upr)" , -2.04% (Lwr)	5mg (Upr), -2mg (Lwr)
106 - 115	<b>110</b>	4.35% (Upr)" , -3.77% (Lwr)	5mg (Upr), -4mg (Lwr)
116 - 127	<b>120</b>	5.51% (Upr)" , -3.45% (Lwr)	7mg (Upr), -4mg (Lwr)
128 - 142	<b>135</b>	4.93% (Upr)" , -5.47% (Lwr)	7mg (Upr), -7mg (Lwr)
143 - 157	<b>150</b>	4.46% (Upr)" , -4.90% (Lwr)	7mg (Upr), -7mg (Lwr)
158 - 172	<b>165</b>	4.07% (Upr)" , -4.43% (Lwr)	7mg (Upr), -7mg (Lwr)
173 - 189	<b>180</b>	4.76% (Upr)" , -4.05% (Lwr)	9mg (Upr), -7mg (Lwr)
190 - 212	<b>200</b>	5.66% (Upr)" , -5.26% (Lwr)	12mg (Upr), -10mg (Lwr)
213 - 237	<b>225</b>	5.06% (Upr)" , -5.63% (Lwr)	12mg (Upr), -12mg (Lwr)
238 - 262	<b>250</b>	4.58% (Upr)" , -5.04% (Lwr)	12mg (Upr), -12mg (Lwr)
263 - 287	<b>275</b>	4.18% (Upr)" , -4.56% (Lwr)	12mg (Upr), -12mg (Lwr)
288 - 315	<b>300</b>	4.76% (Upr)" , -4.17% (Lwr)	15mg (Upr), -12mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## CARFILZOMIB IV INFUSION (Version1)

The dose bands used in this table are constructed based on a 2mg/ml concentration of carfilzomib

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
31 - 33	<b>32</b>	3.03% (Upr)" , -3.23% (Lwr)	1mg (Upr), -1mg (Lwr)
34 - 37	<b>36</b>	2.70% (Upr)" , -5.88% (Lwr)	1mg (Upr), -2mg (Lwr)
38 - 41	<b>40</b>	2.44% (Upr)" , -5.26% (Lwr)	1mg (Upr), -2mg (Lwr)
42 - 45	<b>44</b>	2.22% (Upr)" , -4.76% (Lwr)	1mg (Upr), -2mg (Lwr)
46 - 49	<b>48</b>	2.04% (Upr)" , -4.35% (Lwr)	1mg (Upr), -2mg (Lwr)
50 - 53	<b>52</b>	1.89% (Upr)" , -4.00% (Lwr)	1mg (Upr), -2mg (Lwr)
54 - 57	<b>56</b>	1.75% (Upr)" , -3.70% (Lwr)	1mg (Upr), -2mg (Lwr)
58 - 61	<b>60</b>	1.64% (Upr)" , -3.45% (Lwr)	1mg (Upr), -2mg (Lwr)
62 - 65	<b>64</b>	1.54% (Upr)" , -3.23% (Lwr)	1mg (Upr), -2mg (Lwr)
66 - 70	<b>68</b>	2.86% (Upr)" , -3.03% (Lwr)	2mg (Upr), -2mg (Lwr)
71 - 76	<b>74</b>	2.63% (Upr)" , -4.23% (Lwr)	2mg (Upr), -3mg (Lwr)
77 - 82	<b>80</b>	2.44% (Upr)" , -3.90% (Lwr)	2mg (Upr), -3mg (Lwr)
83 - 88	<b>86</b>	2.27% (Upr)" , -3.61% (Lwr)	2mg (Upr), -3mg (Lwr)
89 - 94	<b>92</b>	2.13% (Upr)" , -3.37% (Lwr)	2mg (Upr), -3mg (Lwr)
95 - 100	<b>98</b>	2.00% (Upr)" , -3.16% (Lwr)	2mg (Upr), -3mg (Lwr)
101 - 106	<b>104</b>	1.89% (Upr)" , -2.97% (Lwr)	2mg (Upr), -3mg (Lwr)
107 - 115	<b>110</b>	4.35% (Upr)" , -2.80% (Lwr)	5mg (Upr), -3mg (Lwr)
116 - 125	<b>120</b>	4.00% (Upr)" , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)
126 - 135	<b>130</b>	3.70% (Upr)" , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)
136 - 145	<b>140</b>	3.45% (Upr)" , -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)
146 - 155	<b>150</b>	3.23% (Upr)" , -2.74% (Lwr)	5mg (Upr), -4mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		



## CARBOPLATIN IV INFUSION (Version 3)

The dose bands used in this table are constructed based on a 10mg/ml concentration of carboplatin

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
57 - 62	60	3.23% (Upr)" , -5.26% (Lwr)	2mg (Upr), -3mg (Lwr)
63 - 69	66	4.35% (Upr)" , -4.76% (Lwr)	3mg (Upr), -3mg (Lwr)
70 - 77	74	3.90% (Upr)" , -5.71% (Lwr)	3mg (Upr), -4mg (Lwr)
78 - 85	82	3.53% (Upr)" , -5.13% (Lwr)	3mg (Upr), -4mg (Lwr)
86 - 94	90	4.26% (Upr)" , -4.65% (Lwr)	4mg (Upr), -4mg (Lwr)
95 - 104	100	3.85% (Upr)" , -5.26% (Lwr)	4mg (Upr), -5mg (Lwr)
105 - 114	110	3.51% (Upr)" , -4.76% (Lwr)	4mg (Upr), -5mg (Lwr)
115 - 124	120	3.23% (Upr)" , -4.35% (Lwr)	4mg (Upr), -5mg (Lwr)
125 - 134	130	2.99% (Upr)" , -4.00% (Lwr)	4mg (Upr), -5mg (Lwr)
135 - 144	140	2.78% (Upr)" , -3.70% (Lwr)	4mg (Upr), -5mg (Lwr)
145 - 154	150	2.60% (Upr)" , -3.45% (Lwr)	4mg (Upr), -5mg (Lwr)
155 - 169	160	5.33% (Upr)" , -3.23% (Lwr)	9mg (Upr), -5mg (Lwr)
170 - 189	180	4.76% (Upr)" , -5.88% (Lwr)	9mg (Upr), -10mg (Lwr)
190 - 209	200	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	220	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	240	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	260	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 294	280	4.76% (Upr)" , -3.70% (Lwr)	14mg (Upr), -10mg (Lwr)
295 - 324	310	4.32% (Upr)" , -5.08% (Lwr)	14mg (Upr), -15mg (Lwr)
325 - 355	340	4.23% (Upr)" , -4.62% (Lwr)	15mg (Upr), -15mg (Lwr)
356 - 385	370	3.90% (Upr)" , -3.93% (Lwr)	15mg (Upr), -14mg (Lwr)
386 - 420	400	4.76% (Upr)" , -3.63% (Lwr)	20mg (Upr), -14mg (Lwr)
421 - 460	440	4.35% (Upr)" , -4.51% (Lwr)	20mg (Upr), -19mg (Lwr)
461 - 500	480	4.00% (Upr)" , -4.12% (Lwr)	20mg (Upr), -19mg (Lwr)
501 - 540	520	3.70% (Upr)" , -3.79% (Lwr)	20mg (Upr), -19mg (Lwr)
541 - 580	560	3.45% (Upr)" , -3.51% (Lwr)	20mg (Upr), -19mg (Lwr)
581 - 625	600	4.00% (Upr)" , -3.27% (Lwr)	25mg (Upr), -19mg (Lwr)
626 - 680	650	4.41% (Upr)" , -3.83% (Lwr)	30mg (Upr), -24mg (Lwr)
681 - 740	710	4.05% (Upr)" , -4.26% (Lwr)	30mg (Upr), -29mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		



CARBOPLATIN IV INFUSION (Version 3) continued			
741 - 810	<b>770</b>	4.94% (Upr)" , -3.91% (Lwr)	40mg (Upr), -29mg (Lwr)
811 - 890	<b>850</b>	4.49% (Upr)" , -4.81% (Lwr)	40mg (Upr), -39mg (Lwr)
891 - 975	<b>930</b>	4.62% (Upr)" , -4.38% (Lwr)	45mg (Upr), -39mg (Lwr)
976 - 1070	<b>1020</b>	4.67% (Upr)" , -4.51% (Lwr)	50mg (Upr), -44mg (Lwr)
1071 - 1170	<b>1120</b>	4.27% (Upr)" , -4.58% (Lwr)	50mg (Upr), -49mg (Lwr)
1171 - 1280	<b>1220</b>	4.69% (Upr)" , -4.18% (Lwr)	60mg (Upr), -49mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## CISPLATIN IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 1mg/ml concentration of cisplatin

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
19 - 21	20	4.76% (Upr)" , -5.26% (Lwr)	1mg (Upr), -1mg (Lwr)
22 - 24	23	4.17% (Upr)" , -4.55% (Lwr)	1mg (Upr), -1mg (Lwr)
25 - 27	26	3.70% (Upr)" , -4.00% (Lwr)	1mg (Upr), -1mg (Lwr)
28 - 30	29	3.33% (Upr)" , -3.57% (Lwr)	1mg (Upr), -1mg (Lwr)
31 - 33	32	3.03% (Upr)" , -3.23% (Lwr)	1mg (Upr), -1mg (Lwr)
34 - 37	35	5.41% (Upr)" , -2.94% (Lwr)	2mg (Upr), -1mg (Lwr)
38 - 42	40	4.76% (Upr)" , -5.26% (Lwr)	2mg (Upr), -2mg (Lwr)
43 - 47	45	4.26% (Upr)" , -4.65% (Lwr)	2mg (Upr), -2mg (Lwr)
48 - 52	50	3.85% (Upr)" , -4.17% (Lwr)	2mg (Upr), -2mg (Lwr)
53 - 57	55	3.51% (Upr)" , -3.77% (Lwr)	2mg (Upr), -2mg (Lwr)
58 - 62	60	3.23% (Upr)" , -3.45% (Lwr)	2mg (Upr), -2mg (Lwr)
63 - 68	66	2.94% (Upr)" , -4.76% (Lwr)	2mg (Upr), -3mg (Lwr)
69 - 76	72	5.26% (Upr)" , -4.35% (Lwr)	4mg (Upr), -3mg (Lwr)
77 - 84	80	4.76% (Upr)" , -3.90% (Lwr)	4mg (Upr), -3mg (Lwr)
85 - 94	90	4.26% (Upr)" , -5.88% (Lwr)	4mg (Upr), -5mg (Lwr)
95 - 104	100	3.85% (Upr)" , -5.26% (Lwr)	4mg (Upr), -5mg (Lwr)
105 - 114	110	3.51% (Upr)" , -4.76% (Lwr)	4mg (Upr), -5mg (Lwr)
115 - 124	120	3.23% (Upr)" , -4.35% (Lwr)	4mg (Upr), -5mg (Lwr)
125 - 134	130	2.99% (Upr)" , -4.00% (Lwr)	4mg (Upr), -5mg (Lwr)
135 - 144	140	2.78% (Upr)" , -3.70% (Lwr)	4mg (Upr), -5mg (Lwr)
145 - 154	150	2.60% (Upr)" , -3.45% (Lwr)	4mg (Upr), -5mg (Lwr)
155 - 169	160	5.33% (Upr)" , -3.23% (Lwr)	9mg (Upr), -5mg (Lwr)
170 - 189	180	4.76% (Upr)" , -5.88% (Lwr)	9mg (Upr), -10mg (Lwr)
190 - 209	200	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	220	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	240	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	260	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 294	280	4.76% (Upr)" , -3.70% (Lwr)	14mg (Upr), -10mg (Lwr)
295 - 324	310	4.32% (Upr)" , -5.08% (Lwr)	14mg (Upr), -15mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## CYCLOPHOSPHAMIDE IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 20mg/ml concentration of cyclophosphamide  
Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
190 - 209	<b>200</b>	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	<b>220</b>	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	<b>240</b>	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	<b>260</b>	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	<b>280</b>	3.11% (Upr)" , -3.70% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 309	<b>300</b>	2.91% (Upr)" , -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	<b>320</b>	2.74% (Upr)" , -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 349	<b>340</b>	2.58% (Upr)" , -3.03% (Lwr)	9mg (Upr), -10mg (Lwr)
350 - 369	<b>360</b>	2.44% (Upr)" , -2.86% (Lwr)	9mg (Upr), -10mg (Lwr)
370 - 399	<b>380</b>	4.76% (Upr)" , -2.70% (Lwr)	19mg (Upr), -10mg (Lwr)
400 - 439	<b>420</b>	4.33% (Upr)" , -5.00% (Lwr)	19mg (Upr), -20mg (Lwr)
440 - 479	<b>460</b>	3.97% (Upr)" , -4.55% (Lwr)	19mg (Upr), -20mg (Lwr)
480 - 529	<b>500</b>	5.48% (Upr)" , -4.17% (Lwr)	29mg (Upr), -20mg (Lwr)
530 - 579	<b>560</b>	3.28% (Upr)" , -5.66% (Lwr)	19mg (Upr), -30mg (Lwr)
580 - 629	<b>600</b>	4.61% (Upr)" , -3.45% (Lwr)	29mg (Upr), -20mg (Lwr)
630 - 689	<b>660</b>	4.21% (Upr)" , -4.76% (Lwr)	29mg (Upr), -30mg (Lwr)
690 - 750	<b>720</b>	4.00% (Upr)" , -4.35% (Lwr)	30mg (Upr), -30mg (Lwr)
751 - 810	<b>780</b>	3.70% (Upr)" , -3.86% (Lwr)	30mg (Upr), -29mg (Lwr)
811 - 880	<b>840</b>	4.55% (Upr)" , -3.58% (Lwr)	40mg (Upr), -29mg (Lwr)
881 - 960	<b>920</b>	4.17% (Upr)" , -4.43% (Lwr)	40mg (Upr), -39mg (Lwr)
961 - 1050	<b>1000</b>	4.76% (Upr)" , -4.06% (Lwr)	50mg (Upr), -39mg (Lwr)
1051 - 1150	<b>1100</b>	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	<b>1200</b>	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	<b>1300</b>	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1470	<b>1400</b>	4.76% (Upr)" , -3.63% (Lwr)	70mg (Upr), -49mg (Lwr)
1471 - 1600	<b>1540</b>	3.75% (Upr)" , -4.69% (Lwr)	60mg (Upr), -69mg (Lwr)
1601 - 1740	<b>1680</b>	3.45% (Upr)" , -4.93% (Lwr)	60mg (Upr), -79mg (Lwr)
1741 - 1900	<b>1820</b>	4.21% (Upr)" , -4.54% (Lwr)	80mg (Upr), -79mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

CYCLOPHOSPHAMIDE IV INFUSION Version 2 (continued)			
1901 - 2100	<b>2000</b>	4.76% (Upr)" , -5.21% (Lwr)	100mg (Upr), -99mg (Lwr)
2101 - 2300	<b>2200</b>	4.35% (Upr)" , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2520	<b>2400</b>	4.76% (Upr)" , -4.30% (Lwr)	120mg (Upr), -99mg (Lwr)
2521 - 2760	<b>2640</b>	4.35% (Upr)" , -4.72% (Lwr)	120mg (Upr), -119mg (Lwr)
2761 - 3040	<b>2900</b>	4.61% (Upr)" , -5.03% (Lwr)	140mg (Upr), -139mg (Lwr)
3041 - 3350	<b>3200</b>	4.48% (Upr)" , -5.23% (Lwr)	150mg (Upr), -159mg (Lwr)
3351 - 3650	<b>3500</b>	4.11% (Upr)" , -4.45% (Lwr)	150mg (Upr), -149mg (Lwr)
3651 - 3990	<b>3800</b>	4.76% (Upr)" , -4.08% (Lwr)	190mg (Upr), -149mg (Lwr)
3991 - 4400	<b>4200</b>	4.55% (Upr)" , -5.24% (Lwr)	200mg (Upr), -209mg (Lwr)
4401 - 4800	<b>4600</b>	4.17% (Upr)" , -4.52% (Lwr)	200mg (Upr), -199mg (Lwr)
4801 - 5250	<b>5000</b>	4.76% (Upr)" , -4.14% (Lwr)	250mg (Upr), -199mg (Lwr)
5251 - 5750	<b>5500</b>	4.35% (Upr)" , -4.74% (Lwr)	250mg (Upr), -249mg (Lwr)
5751 - 6250	<b>6000</b>	4.00% (Upr)" , -4.33% (Lwr)	250mg (Upr), -249mg (Lwr)
6251 - 6750	<b>6500</b>	3.70% (Upr)" , -3.98% (Lwr)	250mg (Upr), -249mg (Lwr)
6751 - 7250	<b>7000</b>	3.45% (Upr)" , -3.69% (Lwr)	250mg (Upr), -249mg (Lwr)
7251 - 7750	<b>7500</b>	3.23% (Upr)" , -3.43% (Lwr)	250mg (Upr), -249mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## CYTARABINE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 100mg/ml concentration of cytarabine

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
125 - 134	<b>130</b>	2.99% (Upr) , -4.00% (Lwr)	4mg (Upr), -5mg (Lwr)
135 - 144	<b>140</b>	2.78% (Upr) , -3.70% (Lwr)	4mg (Upr), -5mg (Lwr)
145 - 154	<b>150</b>	2.60% (Upr) , -3.45% (Lwr)	4mg (Upr), -5mg (Lwr)
155 - 169	<b>160</b>	5.33% (Upr) , -3.23% (Lwr)	9mg (Upr), -5mg (Lwr)
170 - 189	<b>180</b>	4.76% (Upr) , -5.88% (Lwr)	9mg (Upr), -10mg (Lwr)
190 - 209	<b>200</b>	4.31% (Upr) , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	<b>220</b>	3.93% (Upr) , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	<b>240</b>	3.61% (Upr) , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	<b>260</b>	3.35% (Upr) , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	<b>280</b>	3.11% (Upr) , -3.70% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 309	<b>300</b>	2.91% (Upr) , -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	<b>320</b>	2.74% (Upr) , -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 349	<b>340</b>	2.58% (Upr) , -3.03% (Lwr)	9mg (Upr), -10mg (Lwr)
350 - 379	<b>360</b>	5.01% (Upr) , -2.86% (Lwr)	19mg (Upr), -10mg (Lwr)
380 - 419	<b>400</b>	4.53% (Upr) , -5.26% (Lwr)	19mg (Upr), -20mg (Lwr)
420 - 459	<b>440</b>	4.14% (Upr) , -4.76% (Lwr)	19mg (Upr), -20mg (Lwr)
460 - 499	<b>480</b>	3.81% (Upr) , -4.35% (Lwr)	19mg (Upr), -20mg (Lwr)
500 - 539	<b>520</b>	3.53% (Upr) , -4.00% (Lwr)	19mg (Upr), -20mg (Lwr)
540 - 579	<b>560</b>	3.28% (Upr) , -3.70% (Lwr)	19mg (Upr), -20mg (Lwr)
580 - 625	<b>600</b>	4.00% (Upr) , -3.45% (Lwr)	25mg (Upr), -20mg (Lwr)
626 - 675	<b>650</b>	3.70% (Upr) , -3.83% (Lwr)	25mg (Upr), -24mg (Lwr)
676 - 725	<b>700</b>	3.45% (Upr) , -3.55% (Lwr)	25mg (Upr), -24mg (Lwr)
726 - 775	<b>750</b>	3.23% (Upr) , -3.31% (Lwr)	25mg (Upr), -24mg (Lwr)
776 - 825	<b>800</b>	3.03% (Upr) , -3.09% (Lwr)	25mg (Upr), -24mg (Lwr)
826 - 875	<b>850</b>	2.86% (Upr) , -2.91% (Lwr)	25mg (Upr), -24mg (Lwr)
876 - 925	<b>900</b>	2.70% (Upr) , -2.74% (Lwr)	25mg (Upr), -24mg (Lwr)
926 - 975	<b>950</b>	2.56% (Upr) , -2.59% (Lwr)	25mg (Upr), -24mg (Lwr)
976 - 1050	<b>1000</b>	4.76% (Upr) , -2.46% (Lwr)	50mg (Upr), -24mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

CYTARABINE IV INFUSION (Version 1) continued			
1051 - 1150	<b>1100</b>	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	<b>1200</b>	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	<b>1300</b>	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1470	<b>1400</b>	4.76% (Upr)" , -3.63% (Lwr)	70mg (Upr), -49mg (Lwr)
1471 - 1600	<b>1540</b>	3.75% (Upr)" , -4.69% (Lwr)	60mg (Upr), -69mg (Lwr)
1601 - 1740	<b>1680</b>	3.45% (Upr)" , -4.93% (Lwr)	60mg (Upr), -79mg (Lwr)
1741 - 1900	<b>1820</b>	4.21% (Upr)" , -4.54% (Lwr)	80mg (Upr), -79mg (Lwr)
1901 - 2100	<b>2000</b>	4.76% (Upr)" , <b>-5.21% (Lwr)</b>	100mg (Upr), -99mg (Lwr)
2101 - 2300	<b>2200</b>	4.35% (Upr)" , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2520	<b>2400</b>	4.76% (Upr)" , -4.30% (Lwr)	120mg (Upr), -99mg (Lwr)
2521 - 2760	<b>2640</b>	4.35% (Upr)" , -4.72% (Lwr)	120mg (Upr), -119mg (Lwr)
2761 - 3050	<b>2900</b>	4.92% (Upr)" , <b>-5.03% (Lwr)</b>	150mg (Upr), -139mg (Lwr)
3051 - 3350	<b>3200</b>	4.48% (Upr)" , -4.88% (Lwr)	150mg (Upr), -149mg (Lwr)
3351 - 3650	<b>3500</b>	4.11% (Upr)" , -4.45% (Lwr)	150mg (Upr), -149mg (Lwr)
3651 - 3990	<b>3800</b>	4.76% (Upr)" , -4.08% (Lwr)	190mg (Upr), -149mg (Lwr)
3991 - 4400	<b>4200</b>	4.55% (Upr)" , <b>-5.24% (Lwr)</b>	200mg (Upr), -209mg (Lwr)
4401 - 4800	<b>4600</b>	4.17% (Upr)" , -4.52% (Lwr)	200mg (Upr), -199mg (Lwr)
4801 - 5250	<b>5000</b>	4.76% (Upr)" , -4.14% (Lwr)	250mg (Upr), -199mg (Lwr)
5251 - 5750	<b>5500</b>	4.35% (Upr)" , -4.74% (Lwr)	250mg (Upr), -249mg (Lwr)
5751 - 6250	<b>6000</b>	4.00% (Upr)" , -4.33% (Lwr)	250mg (Upr), -249mg (Lwr)
6251 - 6750	<b>6500</b>	3.70% (Upr)" , -3.98% (Lwr)	250mg (Upr), -249mg (Lwr)
6751 - 7250	<b>7000</b>	3.45% (Upr)" , -3.69% (Lwr)	250mg (Upr), -249mg (Lwr)
7251 - 7750	<b>7500</b>	3.23% (Upr)" , -3.43% (Lwr)	250mg (Upr), -249mg (Lwr)
7751 - 8250	<b>8000</b>	3.03% (Upr)" , -3.21% (Lwr)	250mg (Upr), -249mg (Lwr)
8251 - 8750	<b>8500</b>	2.86% (Upr)" , -3.02% (Lwr)	250mg (Upr), -249mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## DACARBAZINE INFUSION (Version 1)

The dose bands used in this table are constructed based on a 20mg/ml concentration of dacarbazine.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
290 - 309	<b>300</b>	2.91% (Upr) , -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	<b>320</b>	2.74% (Upr) , -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 359	<b>340</b>	5.29% (Upr) , -3.03% (Lwr)	19mg (Upr), -10mg (Lwr)
360 - 399	<b>380</b>	4.76% (Upr) , -5.56% (Lwr)	19mg (Upr), -20mg (Lwr)
400 - 439	<b>420</b>	4.33% (Upr) , -5.00% (Lwr)	19mg (Upr), -20mg (Lwr)
440 - 479	<b>460</b>	3.97% (Upr) , -4.55% (Lwr)	19mg (Upr), -20mg (Lwr)
480 - 529	<b>500</b>	5.48% (Upr) , -4.17% (Lwr)	29mg (Upr), -20mg (Lwr)
530 - 579	<b>560</b>	3.28% (Upr) , -5.66% (Lwr)	19mg (Upr), -30mg (Lwr)
580 - 629	<b>600</b>	4.61% (Upr) , -3.45% (Lwr)	29mg (Upr), -20mg (Lwr)
630 - 689	<b>660</b>	4.21% (Upr) , -4.76% (Lwr)	29mg (Upr), -30mg (Lwr)
690 - 750	<b>720</b>	4.00% (Upr) , -4.35% (Lwr)	30mg (Upr), -30mg (Lwr)
751 - 810	<b>780</b>	3.70% (Upr) , -3.86% (Lwr)	30mg (Upr), -29mg (Lwr)
811 - 880	<b>840</b>	4.55% (Upr) , -3.58% (Lwr)	40mg (Upr), -29mg (Lwr)
881 - 960	<b>920</b>	4.17% (Upr) , -4.43% (Lwr)	40mg (Upr), -39mg (Lwr)
961 - 1050	<b>1000</b>	4.76% (Upr) , -4.06% (Lwr)	50mg (Upr), -39mg (Lwr)
1051 - 1150	<b>1100</b>	4.35% (Upr) , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	<b>1200</b>	4.00% (Upr) , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	<b>1300</b>	3.70% (Upr) , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1470	<b>1400</b>	4.76% (Upr) , -3.63% (Lwr)	70mg (Upr), -49mg (Lwr)
1471 - 1600	<b>1540</b>	3.75% (Upr) , -4.69% (Lwr)	60mg (Upr), -69mg (Lwr)
1601 - 1740	<b>1680</b>	3.45% (Upr) , -4.93% (Lwr)	60mg (Upr), -79mg (Lwr)
1741 - 1900	<b>1820</b>	4.21% (Upr) , -4.54% (Lwr)	80mg (Upr), -79mg (Lwr)
1901 - 2100	<b>2000</b>	4.76% (Upr) , -5.21% (Lwr)	100mg (Upr), -99mg (Lwr)
2101 - 2300	<b>2200</b>	4.35% (Upr) , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2500	<b>2400</b>	4.00% (Upr) , -4.30% (Lwr)	100mg (Upr), -99mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## DOCETAXEL IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 20mg/ml concentration of docetaxel.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
31 - 33	<b>32</b>	3.03% (Upr)" , -3.23% (Lwr)	1mg (Upr), -1mg (Lwr)
34 - 37	<b>36</b>	2.70% (Upr)" , -5.88% (Lwr)	1mg (Upr), -2mg (Lwr)
38 - 42	<b>40</b>	4.76% (Upr)" , -5.26% (Lwr)	2mg (Upr), -2mg (Lwr)
43 - 46	<b>44</b>	4.35% (Upr)" , -2.33% (Lwr)	2mg (Upr), -1mg (Lwr)
47 - 50	<b>48</b>	4.00% (Upr)" , -2.13% (Lwr)	2mg (Upr), -1mg (Lwr)
51 - 54	<b>52</b>	3.70% (Upr)" , -1.96% (Lwr)	2mg (Upr), -1mg (Lwr)
55 - 58	<b>56</b>	3.45% (Upr)" , -1.82% (Lwr)	2mg (Upr), -1mg (Lwr)
59 - 62	<b>60</b>	3.23% (Upr)" , -1.69% (Lwr)	2mg (Upr), -1mg (Lwr)
63 - 66	<b>64</b>	3.03% (Upr)" , -1.59% (Lwr)	2mg (Upr), -1mg (Lwr)
67 - 70	<b>68</b>	2.86% (Upr)" , -1.49% (Lwr)	2mg (Upr), -1mg (Lwr)
71 - 75	<b>72</b>	4.00% (Upr)" , -1.41% (Lwr)	3mg (Upr), -1mg (Lwr)
76 - 84	<b>80</b>	4.76% (Upr)" , -5.26% (Lwr)	4mg (Upr), -4mg (Lwr)
85 - 92	<b>88</b>	4.35% (Upr)" , -3.53% (Lwr)	4mg (Upr), -3mg (Lwr)
93 - 100	<b>96</b>	4.00% (Upr)" , -3.23% (Lwr)	4mg (Upr), -3mg (Lwr)
101 - 108	<b>104</b>	3.70% (Upr)" , -2.97% (Lwr)	4mg (Upr), -3mg (Lwr)
109 - 116	<b>112</b>	3.45% (Upr)" , -2.75% (Lwr)	4mg (Upr), -3mg (Lwr)
117 - 126	<b>120</b>	4.76% (Upr)" , -2.56% (Lwr)	6mg (Upr), -3mg (Lwr)
127 - 138	<b>132</b>	4.35% (Upr)" , -3.94% (Lwr)	6mg (Upr), -5mg (Lwr)
139 - 150	<b>144</b>	4.00% (Upr)" , -3.60% (Lwr)	6mg (Upr), -5mg (Lwr)
151 - 162	<b>156</b>	3.70% (Upr)" , -3.31% (Lwr)	6mg (Upr), -5mg (Lwr)
163 - 174	<b>168</b>	3.45% (Upr)" , -3.07% (Lwr)	6mg (Upr), -5mg (Lwr)
175 - 189	<b>180</b>	4.76% (Upr)" , -2.86% (Lwr)	9mg (Upr), -5mg (Lwr)
190 - 209	<b>200</b>	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	<b>220</b>	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	<b>240</b>	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		



## ETOPOSIDE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 20mg/ml concentration of etoposide

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
58 - 62	<b>60</b>	3.23% (Upr)" , -3.45% (Lwr)	2mg (Upr), -2mg (Lwr)
63 - 66	<b>64</b>	3.03% (Upr)" , -1.59% (Lwr)	2mg (Upr), -1mg (Lwr)
67 - 70	<b>68</b>	2.86% (Upr)" , -1.49% (Lwr)	2mg (Upr), -1mg (Lwr)
71 - 76	<b>72</b>	5.26% (Upr)" , -1.41% (Lwr)	4mg (Upr), -1mg (Lwr)
77 - 84	<b>80</b>	4.76% (Upr)" , -3.90% (Lwr)	4mg (Upr), -3mg (Lwr)
85 - 92	<b>88</b>	4.35% (Upr)" , -3.53% (Lwr)	4mg (Upr), -3mg (Lwr)
93 - 100	<b>96</b>	4.00% (Upr)" , -3.23% (Lwr)	4mg (Upr), -3mg (Lwr)
101 - 108	<b>104</b>	3.70% (Upr)" , -2.97% (Lwr)	4mg (Upr), -3mg (Lwr)
109 - 116	<b>112</b>	3.45% (Upr)" , -2.75% (Lwr)	4mg (Upr), -3mg (Lwr)
117 - 126	<b>120</b>	4.76% (Upr)" , -2.56% (Lwr)	6mg (Upr), -3mg (Lwr)
127 - 138	<b>132</b>	4.35% (Upr)" , -3.94% (Lwr)	6mg (Upr), -5mg (Lwr)
139 - 150	<b>144</b>	4.00% (Upr)" , -3.60% (Lwr)	6mg (Upr), -5mg (Lwr)
151 - 162	<b>156</b>	3.70% (Upr)" , -3.31% (Lwr)	6mg (Upr), -5mg (Lwr)
163 - 174	<b>168</b>	3.45% (Upr)" , -3.07% (Lwr)	6mg (Upr), -5mg (Lwr)
175 - 189	<b>180</b>	4.76% (Upr)" , -2.86% (Lwr)	9mg (Upr), -5mg (Lwr)
190 - 209	<b>200</b>	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	<b>220</b>	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	<b>240</b>	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	<b>260</b>	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	<b>280</b>	3.11% (Upr)" , -3.70% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 309	<b>300</b>	2.91% (Upr)" , -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	<b>320</b>	2.74% (Upr)" , -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 349	<b>340</b>	2.58% (Upr)" , -3.03% (Lwr)	9mg (Upr), -10mg (Lwr)
350 - 379	<b>360</b>	5.01% (Upr)" , -2.86% (Lwr)	19mg (Upr), -10mg (Lwr)
380 - 420	<b>400</b>	4.76% (Upr)" , -5.26% (Lwr)	20mg (Upr), -20mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## 5-FLUOROURACIL IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 25mg/ml concentration of 5-fluorouracil

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
238 - 262	<b>250</b>	4.58% (Upr)" , -5.04% (Lwr)	12mg (Upr), -12mg (Lwr)
263 - 287	<b>275</b>	4.18% (Upr)" , -4.56% (Lwr)	12mg (Upr), -12mg (Lwr)
288 - 312	<b>300</b>	3.85% (Upr)" , -4.17% (Lwr)	12mg (Upr), -12mg (Lwr)
313 - 337	<b>325</b>	3.56% (Upr)" , -3.83% (Lwr)	12mg (Upr), -12mg (Lwr)
338 - 362	<b>350</b>	3.31% (Upr)" , -3.55% (Lwr)	12mg (Upr), -12mg (Lwr)
363 - 387	<b>375</b>	3.10% (Upr)" , -3.31% (Lwr)	12mg (Upr), -12mg (Lwr)
388 - 424	<b>400</b>	5.66% (Upr)" , -3.09% (Lwr)	24mg (Upr), -12mg (Lwr)
425 - 474	<b>450</b>	5.06% (Upr)" , -5.88% (Lwr)	24mg (Upr), -25mg (Lwr)
475 - 525	<b>500</b>	4.76% (Upr)" , -5.26% (Lwr)	25mg (Upr), -25mg (Lwr)
526 - 575	<b>550</b>	4.35% (Upr)" , -4.56% (Lwr)	25mg (Upr), -24mg (Lwr)
576 - 625	<b>600</b>	4.00% (Upr)" , -4.17% (Lwr)	25mg (Upr), -24mg (Lwr)
626 - 675	<b>650</b>	3.70% (Upr)" , -3.83% (Lwr)	25mg (Upr), -24mg (Lwr)
676 - 725	<b>700</b>	3.45% (Upr)" , -3.55% (Lwr)	25mg (Upr), -24mg (Lwr)
726 - 775	<b>750</b>	3.23% (Upr)" , -3.31% (Lwr)	25mg (Upr), -24mg (Lwr)
776 - 825	<b>800</b>	3.03% (Upr)" , -3.09% (Lwr)	25mg (Upr), -24mg (Lwr)
826 - 875	<b>850</b>	2.86% (Upr)" , -2.91% (Lwr)	25mg (Upr), -24mg (Lwr)
876 - 925	<b>900</b>	2.70% (Upr)" , -2.74% (Lwr)	25mg (Upr), -24mg (Lwr)
926 - 975	<b>950</b>	2.56% (Upr)" , -2.59% (Lwr)	25mg (Upr), -24mg (Lwr)
976 - 1050	<b>1000</b>	4.76% (Upr)" , -2.46% (Lwr)	50mg (Upr), -24mg (Lwr)
1051 - 1150	<b>1100</b>	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	<b>1200</b>	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	<b>1300</b>	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1450	<b>1400</b>	3.45% (Upr)" , -3.63% (Lwr)	50mg (Upr), -49mg (Lwr)
1451 - 1550	<b>1500</b>	3.23% (Upr)" , -3.38% (Lwr)	50mg (Upr), -49mg (Lwr)
1551 - 1650	<b>1600</b>	3.03% (Upr)" , -3.16% (Lwr)	50mg (Upr), -49mg (Lwr)
1651 - 1775	<b>1700</b>	4.23% (Upr)" , -2.97% (Lwr)	75mg (Upr), -49mg (Lwr)
1776 - 1925	<b>1850</b>	3.90% (Upr)" , -4.17% (Lwr)	75mg (Upr), -74mg (Lwr)
1926 - 2100	<b>2000</b>	4.76% (Upr)" , -3.84% (Lwr)	100mg (Upr), -74mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

5-FLUOROURACIL IV Infusion (Version 2) continued			
2101 - 2300	<b>2200</b>	4.35% (Upr)" , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2500	<b>2400</b>	4.00% (Upr)" , -4.30% (Lwr)	100mg (Upr), -99mg (Lwr)
2501 - 2700	<b>2600</b>	3.70% (Upr)" , -3.96% (Lwr)	100mg (Upr), -99mg (Lwr)
2701 - 2900	<b>2800</b>	3.45% (Upr)" , -3.67% (Lwr)	100mg (Upr), -99mg (Lwr)
2901 - 3150	<b>3000</b>	4.76% (Upr)" , -3.41% (Lwr)	150mg (Upr), -99mg (Lwr)
3151 - 3450	<b>3300</b>	4.35% (Upr)" , -4.73% (Lwr)	150mg (Upr), -149mg (Lwr)
3451 - 3750	<b>3600</b>	4.00% (Upr)" , -4.32% (Lwr)	150mg (Upr), -149mg (Lwr)
3751 - 4050	<b>3900</b>	3.70% (Upr)" , -3.97% (Lwr)	150mg (Upr), -149mg (Lwr)
4051 - 4400	<b>4200</b>	4.55% (Upr)" , -3.68% (Lwr)	200mg (Upr), -149mg (Lwr)
4401 - 4800	<b>4600</b>	4.17% (Upr)" , -4.52% (Lwr)	200mg (Upr), -199mg (Lwr)
4801 - 5200	<b>5000</b>	3.85% (Upr)" , -4.14% (Lwr)	200mg (Upr), -199mg (Lwr)
5201 - 5600	<b>5400</b>	3.57% (Upr)" , -3.83% (Lwr)	200mg (Upr), -199mg (Lwr)
5601 - 6100	<b>5800</b>	4.92% (Upr)" , -3.55% (Lwr)	300mg (Upr), -199mg (Lwr)
6101 - 6700	<b>6400</b>	4.48% (Upr)" , -4.90% (Lwr)	300mg (Upr), -299mg (Lwr)
6701 - 7300	<b>7000</b>	4.11% (Upr)" , -4.46% (Lwr)	300mg (Upr), -299mg (Lwr)
7301 - 8000	<b>7600</b>	5.00% (Upr)" , -4.10% (Lwr)	400mg (Upr), -299mg (Lwr)
8001 - 8800	<b>8400</b>	4.55% (Upr)" , -4.99% (Lwr)	400mg (Upr), -399mg (Lwr)
8801 - 9600	<b>9200</b>	4.17% (Upr)" , -4.53% (Lwr)	400mg (Upr), -399mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## 5-FLUOROURACIL INFUSORS (Version 3)

The dose bands used in this table are constructed based on a 50mg/ml concentration of 5-fluorouracil

Dose Range (mg)	Banded Dose (mg)	Maximum variation range	Maximum variation range (5601 - 6100)
976 - 1050	<b>1000</b>	4.76% (Upr) , -2.46% (Lwr)	50mg (Upr), -24mg (Lwr)
1051 - 1150	<b>1100</b>	4.35% (Upr) , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	<b>1200</b>	4.00% (Upr) , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	<b>1300</b>	3.70% (Upr) , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1450	<b>1400</b>	3.45% (Upr) , -3.63% (Lwr)	50mg (Upr), -49mg (Lwr)
1451 - 1550	<b>1500</b>	3.23% (Upr) , -3.38% (Lwr)	50mg (Upr), -49mg (Lwr)
1551 - 1650	<b>1600</b>	3.03% (Upr) , -3.16% (Lwr)	50mg (Upr), -49mg (Lwr)
1651 - 1775	<b>1700</b>	4.23% (Upr) , -2.97% (Lwr)	75mg (Upr), -49mg (Lwr)
1776 - 1925	<b>1850</b>	3.90% (Upr) , -4.17% (Lwr)	75mg (Upr), -74mg (Lwr)
1926 - 2100	<b>2000</b>	4.76% (Upr) , -3.84% (Lwr)	100mg (Upr), -74mg (Lwr)
2101 - 2300	<b>2200</b>	4.35% (Upr) , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2500	<b>2400</b>	4.00% (Upr) , -4.30% (Lwr)	100mg (Upr), -99mg (Lwr)
2501 - 2700	<b>2600</b>	3.70% (Upr) , -3.96% (Lwr)	100mg (Upr), -99mg (Lwr)
2701 - 2900	<b>2800</b>	3.45% (Upr) , -3.67% (Lwr)	100mg (Upr), -99mg (Lwr)
2901 - 3150	<b>3000</b>	4.76% (Upr) , -3.41% (Lwr)	150mg (Upr), -99mg (Lwr)
3151 - 3450	<b>3300</b>	4.35% (Upr) , -4.73% (Lwr)	150mg (Upr), -149mg (Lwr)
3451 - 3750	<b>3600</b>	4.00% (Upr) , -4.32% (Lwr)	150mg (Upr), -149mg (Lwr)
3751 - 4050	<b>3900</b>	3.70% (Upr) , -3.97% (Lwr)	150mg (Upr), -149mg (Lwr)
4051 - 4400	<b>4200</b>	4.55% (Upr) , -3.68% (Lwr)	200mg (Upr), -149mg (Lwr)
4401 - 4800	<b>4600</b>	4.17% (Upr) , -4.52% (Lwr)	200mg (Upr), -199mg (Lwr)
4801 - 5200	<b>5000</b>	3.85% (Upr) , -4.14% (Lwr)	200mg (Upr), -199mg (Lwr)
5201 - 5600	<b>5400</b>	3.57% (Upr) , -3.83% (Lwr)	200mg (Upr), -199mg (Lwr)
5601 - 6100	<b>5800/ 5750mg*</b>	4.92% (Upr) , -3.55% (Lwr)	300mg (Upr), -199mg (Lwr)
6101 - 6700	<b>6400</b>	4.48% (Upr) , -4.90% (Lwr)	300mg (Upr), -299mg (Lwr)
6701 - 7300	<b>7000</b>	4.11% (Upr) , -4.46% (Lwr)	300mg (Upr), -299mg (Lwr)
7301 - 8000	<b>7600</b>	5.00% (Upr) , -4.10% (Lwr)	400mg (Upr), -299mg (Lwr)
8001 - 8800	<b>8400</b>	4.55% (Upr) , -4.99% (Lwr)	400mg (Upr), -399mg (Lwr)
8801 - 9600	<b>9200</b>	4.17% (Upr) , -4.53% (Lwr)	400mg (Upr), -399mg (Lwr)

\*Please note that for SV 2.5 infusors, the banded dose to be used is 5750mg in order to accommodate the maximum fill volume of the SV2.5.

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## 40mg/ml GEMCITABINE IV INFUSION (Version 4)

The dose bands used in this table are constructed based on a **40mg/ml** concentration of gemcitabine

This table is the nationally recommended dose band table for gemcitabine. An alternate table is supplied for certain sites who use gemcitabine 38mg/ml and wish to dose band locally using this concentration.

**Please note that there are two tables for gemcitabine with different concentrations. Please ensure to use the dose bands applicable to the concentration used in your local site. This should be defined in your dose banding procedures.**

Dose Range (mg)	Dose Band (mg)	Maximum variation range	Maximum variation range (mg)
541 - 580	<b>560</b>	3.45% (Upr)" , -3.51% (Lwr)	20mg (Upr), -19mg (Lwr)
581 - 620	<b>600</b>	3.23% (Upr)" , -3.27% (Lwr)	20mg (Upr), -19mg (Lwr)
621 - 660	<b>640</b>	3.03% (Upr)" , -3.06% (Lwr)	20mg (Upr), -19mg (Lwr)
661 - 700	<b>680</b>	2.86% (Upr)" , -2.87% (Lwr)	20mg (Upr), -19mg (Lwr)
701 - 740	<b>720</b>	2.70% (Upr)" , -2.71% (Lwr)	20mg (Upr), -19mg (Lwr)
741 - 780	<b>760</b>	2.56% (Upr)" , -2.56% (Lwr)	20mg (Upr), -19mg (Lwr)
781 - 820	<b>800</b>	2.44% (Upr)" , -2.43% (Lwr)	20mg (Upr), -19mg (Lwr)
821 - 880	<b>840</b>	4.55% (Upr)" , -2.31% (Lwr)	40mg (Upr), -19mg (Lwr)
881 - 960	<b>920</b>	4.17% (Upr)" , -4.43% (Lwr)	40mg (Upr), -39mg (Lwr)
961 - 1040	<b>1000</b>	3.85% (Upr)" , -4.06% (Lwr)	40mg (Upr), -39mg (Lwr)
1041 - 1120	<b>1080</b>	3.57% (Upr)" , -3.75% (Lwr)	40mg (Upr), -39mg (Lwr)
1121 - 1200	<b>1160</b>	3.33% (Upr)" , -3.48% (Lwr)	40mg (Upr), -39mg (Lwr)
1201 - 1300	<b>1240</b>	4.62% (Upr)" , -3.25% (Lwr)	60mg (Upr), -39mg (Lwr)
1301 - 1420	<b>1360</b>	4.23% (Upr)" , -4.53% (Lwr)	60mg (Upr), -59mg (Lwr)
1421 - 1540	<b>1480</b>	3.90% (Upr)" , -4.15% (Lwr)	60mg (Upr), -59mg (Lwr)
1541 - 1660	<b>1600</b>	3.61% (Upr)" , -3.83% (Lwr)	60mg (Upr), -59mg (Lwr)
1661 - 1780	<b>1720</b>	3.37% (Upr)" , -3.55% (Lwr)	60mg (Upr), -59mg (Lwr)
1781 - 1920	<b>1840</b>	4.17% (Upr)" , -3.31% (Lwr)	80mg (Upr), -59mg (Lwr)
1921 - 2100	<b>2000</b>	4.76% (Upr)" , -4.11% (Lwr)	100mg (Upr), -79mg (Lwr)
2101 - 2300	<b>2200</b>	4.35% (Upr)" , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2500	<b>2400</b>	4.00% (Upr)" , -4.30% (Lwr)	100mg (Upr), -99mg (Lwr)
2501 - 2700	<b>2600</b>	3.70% (Upr)" , -3.96% (Lwr)	100mg (Upr), -99mg (Lwr)
2701 - 2900	<b>2800</b>	3.45% (Upr)" , -3.67% (Lwr)	100mg (Upr), -99mg (Lwr)
2901 - 3100	<b>3000</b>	3.23% (Upr)" , -3.41% (Lwr)	100mg (Upr), -99mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

### 38mg/ml GEMCITABINE IV INFUSION (Version 4)

The dose bands used in this table are constructed based on a **38mg/ml** concentration of gemcitabine

This table is **NOT the nationally recommended** dose band table for gemcitabine. The nationally recommended dose band table is supplied for gemcitabine 40mg/ml. This table is supplied as an alternative for those who wish to use gemcitabine 38mg/ml and dose band locally using this concentration.

**Please note that there are two tables for gemcitabine with different concentrations. Please ensure to use the dose bands applicable to the concentration used in your local site. This should be defined in your dose banding procedures.**

Dose Range (mg)	Dose Band (mg)	Maximum variation range	Maximum variation range (mg)
550 - 589	<b>570</b>	3.23% (Upr)" , -3.64% (Lwr)	19mg (Upr), -20mg (Lwr)
590 - 627	<b>608</b>	3.03% (Upr)" , -3.05% (Lwr)	19mg (Upr), -18mg (Lwr)
628 - 665	<b>646</b>	2.86% (Upr)" , -2.87% (Lwr)	19mg (Upr), -18mg (Lwr)
666 - 703	<b>684</b>	2.70% (Upr)" , -2.70% (Lwr)	19mg (Upr), -18mg (Lwr)
704 - 759	<b>722</b>	4.87% (Upr)" , -2.56% (Lwr)	37mg (Upr), -18mg (Lwr)
760 - 835	<b>798</b>	4.43% (Upr)" , -5.00% (Lwr)	37mg (Upr), -38mg (Lwr)
836 - 912	<b>874</b>	4.17% (Upr)" , -4.55% (Lwr)	38mg (Upr), -38mg (Lwr)
913 - 988	<b>950</b>	3.85% (Upr)" , -4.05% (Lwr)	38mg (Upr), -37mg (Lwr)
989 - 1064	<b>1026</b>	3.57% (Upr)" , -3.74% (Lwr)	38mg (Upr), -37mg (Lwr)
1065 - 1139	<b>1102</b>	3.25% (Upr)" , -3.47% (Lwr)	37mg (Upr), -37mg (Lwr)
1140 - 1216	<b>1178</b>	3.13% (Upr)" , -3.33% (Lwr)	38mg (Upr), -38mg (Lwr)
1217 - 1292	<b>1254</b>	2.94% (Upr)" , -3.04% (Lwr)	38mg (Upr), -37mg (Lwr)
1293 - 1368	<b>1330</b>	2.78% (Upr)" , -2.86% (Lwr)	38mg (Upr), -37mg (Lwr)
1369 - 1520	<b>1444</b>	5.00% (Upr)" , -5.48% (Lwr)	76mg (Upr), -75mg (Lwr)
1521 - 1672	<b>1596</b>	4.55% (Upr)" , -4.93% (Lwr)	76mg (Upr), -75mg (Lwr)
1673 - 1824	<b>1748</b>	4.17% (Upr)" , -4.48% (Lwr)	76mg (Upr), -75mg (Lwr)
1825 - 1995	<b>1900</b>	4.76% (Upr)" , -4.11% (Lwr)	95mg (Upr), -75mg (Lwr)
1996 - 2166	<b>2090</b>	3.51% (Upr)" , -4.71% (Lwr)	76mg (Upr), -94mg (Lwr)
2167 - 2375	<b>2280</b>	4.00% (Upr)" , -5.21% (Lwr)	95mg (Upr), -113mg (Lwr)
2376 - 2565	<b>2470</b>	3.70% (Upr)" , -3.96% (Lwr)	95mg (Upr), -94mg (Lwr)
2566 - 2755	<b>2660</b>	3.45% (Upr)" , -3.66% (Lwr)	95mg (Upr), -94mg (Lwr)
2756 - 2945	<b>2850</b>	3.23% (Upr)" , -3.41% (Lwr)	95mg (Upr), -94mg (Lwr)
2946 - 3150	<b>3040</b>	3.49% (Upr)" , -3.19% (Lwr)	110mg (Upr), -94mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## IRINOTECAN IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 20mg/ml concentration of irinotecan

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
190 - 209	<b>200</b>	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	<b>220</b>	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	<b>240</b>	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	<b>260</b>	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	<b>280</b>	3.11% (Upr)" , -3.70% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 309	<b>300</b>	2.91% (Upr)" , -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	<b>320</b>	2.74% (Upr)" , -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 349	<b>340</b>	2.58% (Upr)" , -3.03% (Lwr)	9mg (Upr), -10mg (Lwr)
350 - 379	<b>360</b>	5.01% (Upr)" , -2.86% (Lwr)	19mg (Upr), -10mg (Lwr)
380 - 419	<b>400</b>	4.53% (Upr)" , -5.26% (Lwr)	19mg (Upr), -20mg (Lwr)
420 - 459	<b>440</b>	4.14% (Upr)" , -4.76% (Lwr)	19mg (Upr), -20mg (Lwr)
460 - 499	<b>480</b>	3.81% (Upr)" , -4.35% (Lwr)	19mg (Upr), -20mg (Lwr)
500 - 539	<b>520</b>	3.53% (Upr)" , -4.00% (Lwr)	19mg (Upr), -20mg (Lwr)
540 - 579	<b>560</b>	3.28% (Upr)" , -3.70% (Lwr)	19mg (Upr), -20mg (Lwr)
580 - 619	<b>600</b>	3.07% (Upr)" , -3.45% (Lwr)	19mg (Upr), -20mg (Lwr)
620 - 659	<b>640</b>	2.88% (Upr)" , -3.23% (Lwr)	19mg (Upr), -20mg (Lwr)
660 - 709	<b>680</b>	4.09% (Upr)" , -3.03% (Lwr)	29mg (Upr), -20mg (Lwr)
710 - 769	<b>740</b>	3.77% (Upr)" , -4.23% (Lwr)	29mg (Upr), -30mg (Lwr)
770 - 830	<b>800</b>	3.61% (Upr)" , -3.90% (Lwr)	30mg (Upr), -30mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		



## METHOTREXATE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 100mg/ml concentration of methotrexate

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
95 - 104	100	3.85% (Upr)" , -5.26% (Lwr)	4mg (Upr), -5mg (Lwr)
105 - 114	110	3.51% (Upr)" , -4.76% (Lwr)	4mg (Upr), -5mg (Lwr)
115 - 124	120	3.23% (Upr)" , -4.35% (Lwr)	4mg (Upr), -5mg (Lwr)
125 - 134	130	2.99% (Upr)" , -4.00% (Lwr)	4mg (Upr), -5mg (Lwr)
135 - 144	140	2.78% (Upr)" , -3.70% (Lwr)	4mg (Upr), -5mg (Lwr)
145 - 154	150	2.60% (Upr)" , -3.45% (Lwr)	4mg (Upr), -5mg (Lwr)
155 - 169	160	5.33% (Upr)" , -3.23% (Lwr)	9mg (Upr), -5mg (Lwr)
170 - 189	180	4.76% (Upr)" , -5.88% (Lwr)	9mg (Upr), -10mg (Lwr)
190 - 209	200	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	220	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	240	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	260	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	280	3.11% (Upr)" , -3.70% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 309	300	2.91% (Upr)" , -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	320	2.74% (Upr)" , -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 349	340	2.58% (Upr)" , -3.03% (Lwr)	9mg (Upr), -10mg (Lwr)
350 - 379	360	5.01% (Upr)" , -2.86% (Lwr)	19mg (Upr), -10mg (Lwr)
380 - 419	400	4.53% (Upr)" , -5.26% (Lwr)	19mg (Upr), -20mg (Lwr)
420 - 459	440	4.14% (Upr)" , -4.76% (Lwr)	19mg (Upr), -20mg (Lwr)
460 - 499	480	3.81% (Upr)" , -4.35% (Lwr)	19mg (Upr), -20mg (Lwr)
500 - 539	520	3.53% (Upr)" , -4.00% (Lwr)	19mg (Upr), -20mg (Lwr)
540 - 579	560	3.28% (Upr)" , -3.70% (Lwr)	19mg (Upr), -20mg (Lwr)
580 - 625	600	4.00% (Upr)" , -3.45% (Lwr)	25mg (Upr), -20mg (Lwr)
626 - 675	650	3.70% (Upr)" , -3.83% (Lwr)	25mg (Upr), -24mg (Lwr)
676 - 725	700	3.45% (Upr)" , -3.55% (Lwr)	25mg (Upr), -24mg (Lwr)
726 - 775	750	3.23% (Upr)" , -3.31% (Lwr)	25mg (Upr), -24mg (Lwr)
776 - 825	800	3.03% (Upr)" , -3.09% (Lwr)	25mg (Upr), -24mg (Lwr)
826 - 875	850	2.86% (Upr)" , -2.91% (Lwr)	25mg (Upr), -24mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		



METHOTREXATE IV INFUSION (Version 1) continued			
876 - 925	<b>900</b>	2.70% (Upr)" , -2.74% (Lwr)	25mg (Upr), -24mg (Lwr)
926 - 975	<b>950</b>	2.56% (Upr)" , -2.59% (Lwr)	25mg (Upr), -24mg (Lwr)
976 - 1050	<b>1000</b>	4.76% (Upr)" , -2.46% (Lwr)	50mg (Upr), -24mg (Lwr)
1051 - 1150	<b>1100</b>	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	<b>1200</b>	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	<b>1300</b>	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1470	<b>1400</b>	4.76% (Upr)" , -3.63% (Lwr)	70mg (Upr), -49mg (Lwr)
1471 - 1600	<b>1540</b>	3.75% (Upr)" , -4.69% (Lwr)	60mg (Upr), -69mg (Lwr)
1601 - 1740	<b>1680</b>	3.45% (Upr)" , -4.93% (Lwr)	60mg (Upr), -79mg (Lwr)
1741 - 1900	<b>1820</b>	4.21% (Upr)" , -4.54% (Lwr)	80mg (Upr), -79mg (Lwr)
1901 - 2100	<b>2000</b>	4.76% (Upr)" , -5.21% (Lwr)	100mg (Upr), -99mg (Lwr)
2101 - 2300	<b>2200</b>	4.35% (Upr)" , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)
2301 - 2520	<b>2400</b>	4.76% (Upr)" , -4.30% (Lwr)	120mg (Upr), -99mg (Lwr)
2521 - 2760	<b>2640</b>	4.35% (Upr)" , -4.72% (Lwr)	120mg (Upr), -119mg (Lwr)
2761 - 3040	<b>2900</b>	4.61% (Upr)" , -5.03% (Lwr)	140mg (Upr), -139mg (Lwr)
3041 - 3350	<b>3200</b>	4.48% (Upr)" , -5.23% (Lwr)	150mg (Upr), -159mg (Lwr)
3351 - 3650	<b>3500</b>	4.11% (Upr)" , -4.45% (Lwr)	150mg (Upr), -149mg (Lwr)
3651 - 3990	<b>3800</b>	4.76% (Upr)" , -4.08% (Lwr)	190mg (Upr), -149mg (Lwr)
3991 - 4400	<b>4200</b>	4.55% (Upr)" , -5.24% (Lwr)	200mg (Upr), -209mg (Lwr)
4401 - 4800	<b>4600</b>	4.17% (Upr)" , -4.52% (Lwr)	200mg (Upr), -199mg (Lwr)
4801 - 5250	<b>5000</b>	4.76% (Upr)" , -4.14% (Lwr)	250mg (Upr), -199mg (Lwr)
5251 - 5750	<b>5500</b>	4.35% (Upr)" , -4.74% (Lwr)	250mg (Upr), -249mg (Lwr)
5751 - 6250	<b>6000</b>	4.00% (Upr)" , -4.33% (Lwr)	250mg (Upr), -249mg (Lwr)
6251 - 6750	<b>6500</b>	3.70% (Upr)" , -3.98% (Lwr)	250mg (Upr), -249mg (Lwr)
6751 - 7250	<b>7000</b>	3.45% (Upr)" , -3.69% (Lwr)	250mg (Upr), -249mg (Lwr)
7251 - 7750	<b>7500</b>	3.23% (Upr)" , -3.43% (Lwr)	250mg (Upr), -249mg (Lwr)
7751 - 8250	<b>8000</b>	3.03% (Upr)" , -3.21% (Lwr)	250mg (Upr), -249mg (Lwr)
8251 - 8750	<b>8500</b>	2.86% (Upr)" , -3.02% (Lwr)	250mg (Upr), -249mg (Lwr)
8751 - 9250	<b>9000</b>	2.70% (Upr)" , -2.85% (Lwr)	250mg (Upr), -249mg (Lwr)
9251 - 9750	<b>9500</b>	2.56% (Upr)" , -2.69% (Lwr)	250mg (Upr), -249mg (Lwr)
9751 - 10500	<b>10000</b>	4.76% (Upr)" , -2.55% (Lwr)	500mg (Upr), -249mg (Lwr)
10501 - 11500	<b>11000</b>	4.35% (Upr)" , -4.75% (Lwr)	500mg (Upr), -499mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

METHOTREXATE IV INFUSION (Version 1) continued			
11501 - 12500	<b>12000</b>	4.00% (Upr)" , -4.34% (Lwr)	500mg (Upr), -499mg (Lwr)
12501 - 13500	<b>13000</b>	3.70% (Upr)" , -3.99% (Lwr)	500mg (Upr), -499mg (Lwr)
13501 - 14500	<b>14000</b>	3.45% (Upr)" , -3.70% (Lwr)	500mg (Upr), -499mg (Lwr)
14501 - 15500	<b>15000</b>	3.23% (Upr)" , -3.44% (Lwr)	500mg (Upr), -499mg (Lwr)
15501 - 16500	<b>16000</b>	3.03% (Upr)" , -3.22% (Lwr)	500mg (Upr), -499mg (Lwr)
16501 - 17500	<b>17000</b>	2.86% (Upr)" , -3.02% (Lwr)	500mg (Upr), -499mg (Lwr)
17501 - 18500	<b>18000</b>	2.70% (Upr)" , -2.85% (Lwr)	500mg (Upr), -499mg (Lwr)
18501 - 19500	<b>19000</b>	2.56% (Upr)" , -2.70% (Lwr)	500mg (Upr), -499mg (Lwr)
19501 - 21000	<b>20000</b>	4.76% (Upr)" , -2.56% (Lwr)	1000mg (Upr), -499mg (Lwr)
21001 - 23000	<b>22000</b>	4.35% (Upr)" , -4.76% (Lwr)	1000mg (Upr), -999mg (Lwr)
23001 - 25000	<b>24000</b>	4.00% (Upr)" , -4.34% (Lwr)	1000mg (Upr), -999mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## NAB-PACLITAXEL IV INFUSION (Version 1.1)

The dose bands used in this table are constructed based on a 5mg/ml concentration of Nab-paclitaxel.

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
116 - 125	<b>120</b>	4.00% (Upr)" , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)
126 - 135	<b>130</b>	3.70% (Upr)" , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)
136 - 145	<b>140</b>	3.45% (Upr)" , -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)
146 - 155	<b>150</b>	3.23% (Upr)" , -2.74% (Lwr)	5mg (Upr), -4mg (Lwr)
156 - 165	<b>160</b>	3.03% (Upr)" , -2.56% (Lwr)	5mg (Upr), -4mg (Lwr)
166 - 176	<b>170</b>	3.41% (Upr)" , -2.41% (Lwr)	6mg (Upr), -4mg (Lwr)
177 - 191	<b>185</b>	3.14% (Upr)" , -4.52% (Lwr)	6mg (Upr), -8mg (Lwr)
192 - 210	<b>200</b>	4.76% (Upr)" , -4.17% (Lwr)	10mg (Upr), -8mg (Lwr)
211 - 230	<b>220</b>	4.35% (Upr)" , -4.27% (Lwr)	10mg (Upr), -9mg (Lwr)
231 - 250	<b>240</b>	4.00% (Upr)" , -3.90% (Lwr)	10mg (Upr), -9mg (Lwr)
251 - 270	<b>260</b>	3.70% (Upr)" , -3.59% (Lwr)	10mg (Upr), -9mg (Lwr)
271 - 290	<b>280</b>	3.45% (Upr)" , -3.32% (Lwr)	10mg (Upr), -9mg (Lwr)
291 - 315	<b>300</b>	4.76% (Upr)" , -3.09% (Lwr)	15mg (Upr), -9mg (Lwr)
316 - 340	<b>325</b>	4.41% (Upr)" , -2.85% (Lwr)	15mg (Upr), -9mg (Lwr)
341 - 365	<b>350</b>	4.11% (Upr)" , -2.64% (Lwr)	15mg (Upr), -9mg (Lwr)
366 - 390	<b>375</b>	3.85% (Upr)" , -2.46% (Lwr)	15mg (Upr), -9mg (Lwr)
391 - 420	<b>400</b>	4.76% (Upr)" , -2.30% (Lwr)	20mg (Upr), -9mg (Lwr)
421 - 460	<b>440</b>	4.35% (Upr)" , -4.51% (Lwr)	20mg (Upr), -19mg (Lwr)
461 - 500	<b>480</b>	4.00% (Upr)" , -4.12% (Lwr)	20mg (Upr), -19mg (Lwr)
501 - 540	<b>520</b>	3.70% (Upr)" , -3.79% (Lwr)	20mg (Upr), -19mg (Lwr)
541 - 580	<b>560</b>	3.45% (Upr)" , -3.51% (Lwr)	20mg (Upr), -19mg (Lwr)
581 - 620	<b>600</b>	3.23% (Upr)" , -3.27% (Lwr)	20mg (Upr), -19mg (Lwr)
621 - 660	<b>640</b>	3.03% (Upr)" , -3.06% (Lwr)	20mg (Upr), -19mg (Lwr)
661 - 700	<b>680</b>	2.86% (Upr)" , -2.87% (Lwr)	20mg (Upr), -19mg (Lwr)
701 - 740	<b>720</b>	2.70% (Upr)" , -2.71% (Lwr)	20mg (Upr), -19mg (Lwr)
741 - 780	<b>760</b>	2.56% (Upr)" , -2.56% (Lwr)	20mg (Upr), -19mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## OXALIPLATIN IV INFUSION (Version 3)

The dose bands used in this table are constructed based on a 5mg/ml concentration of oxaliplatin

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
58 - 62	<b>60</b>	3.23% (Upr)" , -3.45% (Lwr)	2mg (Upr), -2mg (Lwr)
63 - 67	<b>65</b>	2.99% (Upr)" , -3.17% (Lwr)	2mg (Upr), -2mg (Lwr)
68 - 72	<b>70</b>	2.78% (Upr)" , -2.94% (Lwr)	2mg (Upr), -2mg (Lwr)
73 - 77	<b>75</b>	2.60% (Upr)" , -2.74% (Lwr)	2mg (Upr), -2mg (Lwr)
78 - 84	<b>80</b>	4.76% (Upr)" , -2.56% (Lwr)	4mg (Upr), -2mg (Lwr)
85 - 94	<b>90</b>	4.26% (Upr)" , -5.88% (Lwr)	4mg (Upr), -5mg (Lwr)
95 - 105	<b>100</b>	4.76% (Upr)" , -5.26% (Lwr)	5mg (Upr), -5mg (Lwr)
106 - 115	<b>110</b>	4.35% (Upr)" , -3.77% (Lwr)	5mg (Upr), -4mg (Lwr)
116 - 125	<b>120</b>	4.00% (Upr)" , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)
126 - 135	<b>130</b>	3.70% (Upr)" , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)
136 - 145	<b>140</b>	3.45% (Upr)" , -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)
146 - 155	<b>150</b>	3.23% (Upr)" , -2.74% (Lwr)	5mg (Upr), -4mg (Lwr)
156 - 165	<b>160</b>	3.03% (Upr)" , -2.56% (Lwr)	5mg (Upr), -4mg (Lwr)
166 - 175	<b>170</b>	2.86% (Upr)" , -2.41% (Lwr)	5mg (Upr), -4mg (Lwr)
176 - 190	<b>185</b>	2.63% (Upr)" , -5.11% (Lwr)	5mg (Upr), -9mg (Lwr)
191 - 210	<b>200</b>	4.76% (Upr)" , -4.71% (Lwr)	10mg (Upr), -9mg (Lwr)
211 - 230	<b>220</b>	4.35% (Upr)" , -4.27% (Lwr)	10mg (Upr), -9mg (Lwr)
231 - 250	<b>240</b>	4.00% (Upr)" , -3.90% (Lwr)	10mg (Upr), -9mg (Lwr)
251 - 270	<b>260</b>	3.70% (Upr)" , -3.59% (Lwr)	10mg (Upr), -9mg (Lwr)
271 - 290	<b>280</b>	3.45% (Upr)" , -3.32% (Lwr)	10mg (Upr), -9mg (Lwr)
291 - 310	<b>300</b>	3.23% (Upr)" , -3.09% (Lwr)	10mg (Upr), -9mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## PACLITAXEL IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 6mg/ml concentration of paclitaxel

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
57 - 63	<b>60</b>	4.76% (Upr)" <b>-5.26% (Lwr)</b>	3mg (Upr), -3mg (Lwr)
64 - 69	<b>66</b>	4.35% (Upr)" , -3.13% (Lwr)	3mg (Upr), -2mg (Lwr)
70 - 75	<b>72</b>	4.00% (Upr)" , -2.86% (Lwr)	3mg (Upr), -2mg (Lwr)
76 - 81	<b>78</b>	3.70% (Upr)" , -2.63% (Lwr)	3mg (Upr), -2mg (Lwr)
82 - 86	<b>84</b>	2.33% (Upr)" , -2.44% (Lwr)	2mg (Upr), -2mg (Lwr)
87 - 93	<b>90</b>	3.23% (Upr)" , -3.45% (Lwr)	3mg (Upr), -3mg (Lwr)
94 - 99	<b>96</b>	3.03% (Upr)" , -2.13% (Lwr)	3mg (Upr), -2mg (Lwr)
100 - 105	<b>102</b>	2.86% (Upr)" , -2.00% (Lwr)	3mg (Upr), -2mg (Lwr)
106 - 113	<b>108</b>	4.42% (Upr)" , -1.89% (Lwr)	5mg (Upr), -2mg (Lwr)
114 - 126	<b>120</b>	4.76% (Upr)" , <b>-5.26% (Lwr)</b>	6mg (Upr), -6mg (Lwr)
127 - 138	<b>132</b>	4.35% (Upr)" , -3.94% (Lwr)	6mg (Upr), -5mg (Lwr)
139 - 150	<b>144</b>	4.00% (Upr)" , -3.60% (Lwr)	6mg (Upr), -5mg (Lwr)
151 - 162	<b>156</b>	3.70% (Upr)" , -3.31% (Lwr)	6mg (Upr), -5mg (Lwr)
163 - 174	<b>168</b>	3.45% (Upr)" , -3.07% (Lwr)	6mg (Upr), -5mg (Lwr)
175 - 186	<b>180</b>	3.23% (Upr)" , -2.86% (Lwr)	6mg (Upr), -5mg (Lwr)
187 - 198	<b>192</b>	3.03% (Upr)" , -2.67% (Lwr)	6mg (Upr), -5mg (Lwr)
199 - 210	<b>204</b>	2.86% (Upr)" , -2.51% (Lwr)	6mg (Upr), -5mg (Lwr)
211 - 222	<b>216</b>	2.70% (Upr)" , -2.37% (Lwr)	6mg (Upr), -5mg (Lwr)
223 - 246	<b>234</b>	4.88% (Upr)" , -4.93% (Lwr)	12mg (Upr), -11mg (Lwr)
247 - 264	<b>252</b>	4.55% (Upr)" , -2.02% (Lwr)	12mg (Upr), -5mg (Lwr)
265 - 282	<b>270</b>	4.26% (Upr)" , -1.89% (Lwr)	12mg (Upr), -5mg (Lwr)
283 - 306	<b>294</b>	3.92% (Upr)" , -3.89% (Lwr)	12mg (Upr), -11mg (Lwr)
307 - 330	<b>318</b>	3.64% (Upr)" , -3.58% (Lwr)	12mg (Upr), -11mg (Lwr)
331 - 354	<b>342</b>	3.39% (Upr)" , -3.32% (Lwr)	12mg (Upr), -11mg (Lwr)
355 - 378	<b>366</b>	3.17% (Upr)" , -3.10% (Lwr)	12mg (Upr), -11mg (Lwr)
379 - 402	<b>390</b>	2.99% (Upr)" , -2.90% (Lwr)	12mg (Upr), -11mg (Lwr)
403 - 426	<b>414</b>	2.82% (Upr)" , -2.73% (Lwr)	12mg (Upr), -11mg (Lwr)
427 - 450	<b>438</b>	2.67% (Upr)" , -2.58% (Lwr)	12mg (Upr), -11mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## PEMETREXED IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 25mg/ml concentration of pemetrexed

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
475-524	<b>500</b>	4.58% (Upr)" , -5.26% (Lwr)	24mg (Upr), -25mg (Lwr)
525-574	<b>550</b>	4.18% (Upr)" , -4.76% (Lwr)	24mg (Upr), -25mg (Lwr)
575-624	<b>600</b>	3.85% (Upr)" , -4.35% (Lwr)	24mg (Upr), -25mg (Lwr)
625-674	<b>650</b>	3.56% (Upr)" , -4.00% (Lwr)	24mg (Upr), -25mg (Lwr)
675-724	<b>700</b>	3.31% (Upr)" , -3.70% (Lwr)	24mg (Upr), -25mg (Lwr)
725-785	<b>750</b>	4.46% (Upr)" , -3.45% (Lwr)	35mg (Upr), -25mg (Lwr)
786-859	<b>825</b>	3.96% (Upr)" , -4.96% (Lwr)	34mg (Upr), -39mg (Lwr)
860-949	<b>900</b>	5.16% (Upr)" , -4.65% (Lwr)	49mg (Upr), -40mg (Lwr)
950-1049	<b>1000</b>	4.67% (Upr)" , -5.26% (Lwr)	49mg (Upr), -50mg (Lwr)
1050-1149	<b>1100</b>	4.26% (Upr)" , -4.76% (Lwr)	49mg (Upr), -50mg (Lwr)
1150-1249	<b>1200</b>	3.92% (Upr)" , -4.35% (Lwr)	49mg (Upr), -50mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## TRASTUZUMAB EMTANSINE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 20mg/ml concentration of trastuzumab emtansine. Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
65 - 72	<b>68</b>	5.56% (Upr)" , -4.62% (Lwr)	4mg (Upr), -3mg (Lwr)
73 - 80	<b>76</b>	5.00% (Upr)" , -4.11% (Lwr)	4mg (Upr), -3mg (Lwr)
81 - 88	<b>84</b>	4.55% (Upr)" , -3.70% (Lwr)	4mg (Upr), -3mg (Lwr)
89 - 96	<b>92</b>	4.17% (Upr)" , -3.37% (Lwr)	4mg (Upr), -3mg (Lwr)
97 - 104	<b>100</b>	3.85% (Upr)" , -3.09% (Lwr)	4mg (Upr), -3mg (Lwr)
105 - 114	<b>108</b>	5.26% (Upr)" , -2.86% (Lwr)	6mg (Upr), -3mg (Lwr)
115 - 126	<b>120</b>	4.76% (Upr)" , -4.35% (Lwr)	6mg (Upr), -5mg (Lwr)
127 - 138	<b>132</b>	4.35% (Upr)" , -3.94% (Lwr)	6mg (Upr), -5mg (Lwr)
139 - 150	<b>144</b>	4.00% (Upr)" , -3.60% (Lwr)	6mg (Upr), -5mg (Lwr)
151 - 162	<b>156</b>	3.70% (Upr)" , -3.31% (Lwr)	6mg (Upr), -5mg (Lwr)
163 - 174	<b>168</b>	3.45% (Upr)" , -3.07% (Lwr)	6mg (Upr), -5mg (Lwr)
175 - 189	<b>180</b>	4.76% (Upr)" , -2.86% (Lwr)	9mg (Upr), -5mg (Lwr)
190 - 209	<b>200</b>	4.31% (Upr)" , -5.26% (Lwr)	9mg (Upr), -10mg (Lwr)
210 - 229	<b>220</b>	3.93% (Upr)" , -4.76% (Lwr)	9mg (Upr), -10mg (Lwr)
230 - 249	<b>240</b>	3.61% (Upr)" , -4.35% (Lwr)	9mg (Upr), -10mg (Lwr)
250 - 269	<b>260</b>	3.35% (Upr)" , -4.00% (Lwr)	9mg (Upr), -10mg (Lwr)
270 - 289	<b>280</b>	3.11% (Upr)" , -3.70% (Lwr)	9mg (Upr), -10mg (Lwr)
290 - 309	<b>300</b>	2.91% (Upr)" , -3.45% (Lwr)	9mg (Upr), -10mg (Lwr)
310 - 329	<b>320</b>	2.74% (Upr)" , -3.23% (Lwr)	9mg (Upr), -10mg (Lwr)
330 - 349	<b>340</b>	2.58% (Upr)" , -3.03% (Lwr)	9mg (Upr), -10mg (Lwr)
350 - 379	<b>360</b>	5.01% (Upr)" , -2.86% (Lwr)	19mg (Upr), -10mg (Lwr)
380 - 419	<b>400</b>	4.53% (Upr)" , -5.26% (Lwr)	19mg (Upr), -20mg (Lwr)
420 - 459	<b>440</b>	4.14% (Upr)" , -4.76% (Lwr)	19mg (Upr), -20mg (Lwr)
460 - 499	<b>480</b>	3.81% (Upr)" , -4.35% (Lwr)	19mg (Upr), -20mg (Lwr)
500 - 539	<b>520</b>	3.53% (Upr)" , -4.00% (Lwr)	19mg (Upr), -20mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## VINORELBINE IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 10mg/ml concentration of vinorelbine

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
19 - 21	20	4.76% (Upr)" , -5.26% (Lwr)	1mg (Upr), -1mg (Lwr)
21.1 - 23	22	4.35% (Upr)" , -4.27% (Lwr)	1mg (Upr), -0.9mg (Lwr)
23.1 - 25	24	4.00% (Upr)" , -3.90% (Lwr)	1mg (Upr), -0.9mg (Lwr)
25.1 - 27	26	3.70% (Upr)" , -3.59% (Lwr)	1mg (Upr), -0.9mg (Lwr)
27.1 - 29	28	3.45% (Upr)" , -3.32% (Lwr)	1mg (Upr), -0.9mg (Lwr)
29.1 - 32	30	6.25% (Upr)" , -3.09% (Lwr)	2mg (Upr), -0.9mg (Lwr)
33 - 36	34	5.56% (Upr)" , -3.03% (Lwr)	2mg (Upr), -1mg (Lwr)
37 - 40	38	5.00% (Upr)" , -2.70% (Lwr)	2mg (Upr), -1mg (Lwr)
41 - 44	42	4.55% (Upr)" , -2.44% (Lwr)	2mg (Upr), -1mg (Lwr)
45 - 48	46	4.17% (Upr)" , -2.22% (Lwr)	2mg (Upr), -1mg (Lwr)
49 - 51	50	1.96% (Upr)" , -2.04% (Lwr)	1mg (Upr), -1mg (Lwr)
52 - 57	54	5.26% (Upr)" , -3.85% (Lwr)	3mg (Upr), -2mg (Lwr)
58 - 63	60	4.76% (Upr)" , -3.45% (Lwr)	3mg (Upr), -2mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		



## DOSE BANDING TABLES – MONOCLONALS FOR INTRAVENOUS INFUSION

### MONOCLONALS - BEVACIZUMAB IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 25mg/ml concentration of bevacizumab

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
190 - 211	<b>200</b>	5.21% (Upr)" , -5.26% (Lwr)	11mg (Upr), -10mg (Lwr)
212 - 236	<b>225</b>	4.66% (Upr)" , -6.13% (Lwr)	11mg (Upr), -13mg (Lwr)
237 - 261	<b>250</b>	4.21% (Upr)" , -5.49% (Lwr)	11mg (Upr), -13mg (Lwr)
262 - 286	<b>275</b>	3.85% (Upr)" , -4.96% (Lwr)	11mg (Upr), -13mg (Lwr)
287 - 311	<b>300</b>	3.54% (Upr)" , -4.53% (Lwr)	11mg (Upr), -13mg (Lwr)
312 - 336	<b>325</b>	3.27% (Upr)" , -4.17% (Lwr)	11mg (Upr), -13mg (Lwr)
337 - 361	<b>350</b>	3.05% (Upr)" , -3.86% (Lwr)	11mg (Upr), -13mg (Lwr)
362 - 386	<b>375</b>	2.85% (Upr)" , -3.59% (Lwr)	11mg (Upr), -13mg (Lwr)
387 - 411	<b>400</b>	2.68% (Upr)" , -3.36% (Lwr)	11mg (Upr), -13mg (Lwr)
412 - 436	<b>425</b>	2.52% (Upr)" , -3.16% (Lwr)	11mg (Upr), -13mg (Lwr)
437 - 461	<b>450</b>	2.39% (Upr)" , -2.97% (Lwr)	11mg (Upr), -13mg (Lwr)
462 - 486	<b>475</b>	2.26% (Upr)" , -2.81% (Lwr)	11mg (Upr), -13mg (Lwr)
487 - 525	<b>500</b>	4.76% (Upr)" , -2.67% (Lwr)	25mg (Upr), -13mg (Lwr)
526 - 575	<b>550</b>	4.35% (Upr)" , -4.56% (Lwr)	25mg (Upr), -24mg (Lwr)
576 - 625	<b>600</b>	4.00% (Upr)" , -4.17% (Lwr)	25mg (Upr), -24mg (Lwr)
626 - 675	<b>650</b>	3.70% (Upr)" , -3.83% (Lwr)	25mg (Upr), -24mg (Lwr)
676 - 725	<b>700</b>	3.45% (Upr)" , -3.55% (Lwr)	25mg (Upr), -24mg (Lwr)
726 - 775	<b>750</b>	3.23% (Upr)" , -3.31% (Lwr)	25mg (Upr), -24mg (Lwr)
776 - 825	<b>800</b>	3.03% (Upr)" , -3.09% (Lwr)	25mg (Upr), -24mg (Lwr)
826 - 875	<b>850</b>	2.86% (Upr)" , -2.91% (Lwr)	25mg (Upr), -24mg (Lwr)
876 - 925	<b>900</b>	2.70% (Upr)" , -2.74% (Lwr)	25mg (Upr), -24mg (Lwr)
926 - 975	<b>950</b>	2.56% (Upr)" , -2.59% (Lwr)	25mg (Upr), -24mg (Lwr)
976 - 1050	<b>1000</b>	4.76% (Upr)" , -2.46% (Lwr)	50mg (Upr), -24mg (Lwr)
1051 - 1150	<b>1100</b>	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	<b>1200</b>	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

BEVACIZUMAB IV INFUSION (Version 2) continued:			
1251 - 1350	<b>1300</b>	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1450	<b>1400</b>	3.45% (Upr)" , -3.63% (Lwr)	50mg (Upr), -49mg (Lwr)
1451 - 1575	<b>1500</b>	4.76% (Upr)" , -3.38% (Lwr)	75mg (Upr), -49mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## MONOCLONALS – CETUXIMAB IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 5mg/ml concentration of cetuximab.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
365 - 400	<b>385</b>	3.75% (Upr)" , -5.00% (Lwr)	15mg (Upr), -20mg (Lwr)
401 - 440	<b>420</b>	4.55% (Upr)" , -4.32% (Lwr)	20mg (Upr), -19mg (Lwr)
441 - 480	<b>460</b>	4.17% (Upr)" , -3.96% (Lwr)	20mg (Upr), -19mg (Lwr)
481 - 520	<b>500</b>	3.85% (Upr)" , -3.65% (Lwr)	20mg (Upr), -19mg (Lwr)
521 - 560	<b>540</b>	3.57% (Upr)" , -3.39% (Lwr)	20mg (Upr), -19mg (Lwr)
561 - 610	<b>590</b>	3.28% (Upr)" , -4.75% (Lwr)	20mg (Upr), -29mg (Lwr)
611 - 670	<b>640</b>	4.48% (Upr)" , -4.33% (Lwr)	30mg (Upr), -29mg (Lwr)
671 - 730	<b>700</b>	4.11% (Upr)" , -3.97% (Lwr)	30mg (Upr), -29mg (Lwr)
731 - 790	<b>760</b>	3.80% (Upr)" , -3.67% (Lwr)	30mg (Upr), -29mg (Lwr)
791 - 870	<b>830</b>	4.60% (Upr)" , -4.48% (Lwr)	40mg (Upr), -39mg (Lwr)
871 - 950	<b>910</b>	4.21% (Upr)" , -4.11% (Lwr)	40mg (Upr), -39mg (Lwr)
951 - 1050	<b>1000</b>	4.76% (Upr)" , -4.67% (Lwr)	50mg (Upr), -49mg (Lwr)
1051 - 1150	<b>1100</b>	4.35% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	<b>1200</b>	4.00% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## MONOCLONALS- DARATUMUMAB INFUSION (Version 1)

The dose bands used in this table are constructed based on a 20mg/ml concentration of daratumumab.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
400 - 439	<b>420</b>	4.33% (Upr)" , -5.00% (Lwr)	19mg (Upr), -20mg (Lwr)
440 - 479	<b>460</b>	3.97% (Upr)" , -4.55% (Lwr)	19mg (Upr), -20mg (Lwr)
480 - 529	<b>500</b>	5.48% (Upr)" , -4.17% (Lwr)	29mg (Upr), -20mg (Lwr)
530 - 579	<b>560</b>	3.28% (Upr)" , -5.66% (Lwr)	19mg (Upr), -30mg (Lwr)
580 - 629	<b>600</b>	4.61% (Upr)" , -3.45% (Lwr)	29mg (Upr), -20mg (Lwr)
630 - 689	<b>660</b>	4.21% (Upr)" , -4.76% (Lwr)	29mg (Upr), -30mg (Lwr)
690 - 750	<b>720</b>	4.00% (Upr)" , -4.35% (Lwr)	30mg (Upr), -30mg (Lwr)
751 - 810	<b>780</b>	3.70% (Upr)" , -3.86% (Lwr)	30mg (Upr), -29mg (Lwr)
811 - 880	<b>840</b>	4.55% (Upr)" , -3.58% (Lwr)	40mg (Upr), -29mg (Lwr)
881 - 960	<b>920</b>	4.17% (Upr)" , -4.43% (Lwr)	40mg (Upr), -39mg (Lwr)
961 - 1050	<b>1000</b>	4.76% (Upr)" , -4.06% (Lwr)	50mg (Upr), -39mg (Lwr)
1051 - 1150	<b>1100</b>	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	<b>1200</b>	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	<b>1300</b>	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)
1351 - 1470	<b>1400</b>	4.76% (Upr)" , -3.63% (Lwr)	70mg (Upr), -49mg (Lwr)
1471 - 1600	<b>1540</b>	3.75% (Upr)" , -4.69% (Lwr)	60mg (Upr), -69mg (Lwr)
1601 - 1740	<b>1680</b>	3.45% (Upr)" , -4.93% (Lwr)	60mg (Upr), -79mg (Lwr)
1741 - 1900	<b>1820</b>	4.21% (Upr)" , -4.54% (Lwr)	80mg (Upr), -79mg (Lwr)
1901 - 2100	<b>2000</b>	4.76% (Upr)" -5.21% (Lwr)	100mg (Upr), -99mg (Lwr)
2101 - 2300	<b>2200</b>	4.35% (Upr)" , -4.71% (Lwr)	100mg (Upr), -99mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## MONOCLONALS – IPILIMUMAB IV INFUSION (Version 1)

The dose bands used in this table are constructed based on a 5mg/ml concentration of ipilimumab

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
116 - 125	<b>120</b>	4.00% (Upr)" , -3.45% (Lwr)	5mg (Upr), -4mg (Lwr)
126 - 135	<b>130</b>	3.70% (Upr)" , -3.17% (Lwr)	5mg (Upr), -4mg (Lwr)
136 - 145	<b>140</b>	3.45% (Upr)" , -2.94% (Lwr)	5mg (Upr), -4mg (Lwr)
146 - 155	<b>150</b>	3.23% (Upr)" , -2.74% (Lwr)	5mg (Upr), -4mg (Lwr)
156 - 165	<b>160</b>	3.03% (Upr)" , -2.56% (Lwr)	5mg (Upr), -4mg (Lwr)
166 - 175	<b>170</b>	2.86% (Upr)" , -2.41% (Lwr)	5mg (Upr), -4mg (Lwr)
176 - 185	<b>180</b>	2.70% (Upr)" , -2.27% (Lwr)	5mg (Upr), -4mg (Lwr)
186 - 195	<b>190</b>	2.56% (Upr)" , -2.15% (Lwr)	5mg (Upr), -4mg (Lwr)
196 - 210	<b>200</b>	4.76% (Upr)" , -2.04% (Lwr)	10mg (Upr), -4mg (Lwr)
211 - 230	<b>220</b>	4.35% (Upr)" , -4.27% (Lwr)	10mg (Upr), -9mg (Lwr)
231 - 250	<b>240</b>	4.00% (Upr)" , -3.90% (Lwr)	10mg (Upr), -9mg (Lwr)
251 - 270	<b>260</b>	3.70% (Upr)" , -3.59% (Lwr)	10mg (Upr), -9mg (Lwr)
271 - 290	<b>280</b>	3.45% (Upr)" , -3.32% (Lwr)	10mg (Upr), -9mg (Lwr)
291 - 310	<b>300</b>	3.23% (Upr)" , -3.09% (Lwr)	10mg (Upr), -9mg (Lwr)
311 - 330	<b>320</b>	3.03% (Upr)" , -2.89% (Lwr)	10mg (Upr), -9mg (Lwr)
331 - 350	<b>340</b>	2.86% (Upr)" , -2.72% (Lwr)	10mg (Upr), -9mg (Lwr)
351 - 370	<b>360</b>	2.70% (Upr)" , -2.56% (Lwr)	10mg (Upr), -9mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## MONOCLONALS – RITUXIMAB IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 10mg/ml concentration of rituximab.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
475 - 525	<b>500</b>	4.76% (Upr)" , -5.26% (Lwr)	25mg (Upr), -25mg (Lwr)
526 - 575	<b>550</b>	4.35% (Upr)" , -4.56% (Lwr)	25mg (Upr), -24mg (Lwr)
576 - 625	<b>600</b>	4.00% (Upr)" , -4.17% (Lwr)	25mg (Upr), -24mg (Lwr)
626 - 675	<b>650</b>	3.70% (Upr)" , -3.83% (Lwr)	25mg (Upr), -24mg (Lwr)
676 - 725	<b>700</b>	3.45% (Upr)" , -3.55% (Lwr)	25mg (Upr), -24mg (Lwr)
726 - 775	<b>750</b>	3.23% (Upr)" , -3.31% (Lwr)	25mg (Upr), -24mg (Lwr)
776 - 825	<b>800</b>	3.03% (Upr)" , -3.09% (Lwr)	25mg (Upr), -24mg (Lwr)
826 - 875	<b>850</b>	2.86% (Upr)" , -2.91% (Lwr)	25mg (Upr), -24mg (Lwr)
876 - 925	<b>900</b>	2.70% (Upr)" , -2.74% (Lwr)	25mg (Upr), -24mg (Lwr)
926 - 975	<b>950</b>	2.56% (Upr)" , -2.59% (Lwr)	25mg (Upr), -24mg (Lwr)
976 - 1050	<b>1000</b>	4.76% (Upr)" , -2.46% (Lwr)	50mg (Upr), -24mg (Lwr)
1051 - 1150	<b>1100</b>	4.35% (Upr)" , -4.66% (Lwr)	50mg (Upr), -49mg (Lwr)
1151 - 1250	<b>1200</b>	4.00% (Upr)" , -4.26% (Lwr)	50mg (Upr), -49mg (Lwr)
1251 - 1350	<b>1300</b>	3.70% (Upr)" , -3.92% (Lwr)	50mg (Upr), -49mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## MONOCLONALS - TRASTUZUMAB IV INFUSION (Version 2)

The dose bands used in this table are constructed based on a 21mg/ml concentration of trastuzumab

Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)
95 - 115	105	8.70% (Upr)" , -10.53% (Lwr)	10mg (Upr), -10mg (Lwr)
116 - 136	126	7.35% (Upr)" , -8.62% (Lwr)	10mg (Upr), -10mg (Lwr)
137 - 157	147	6.37% (Upr)" , -7.30% (Lwr)	10mg (Upr), -10mg (Lwr)
158 - 178	168	5.62% (Upr)" , -6.33% (Lwr)	10mg (Upr), -10mg (Lwr)
179 - 199	189	5.03% (Upr)" , -5.59% (Lwr)	10mg (Upr), -10mg (Lwr)
200 - 220	210	4.55% (Upr)" , -5.00% (Lwr)	10mg (Upr), -10mg (Lwr)
221 - 241	231	4.15% (Upr)" , -4.52% (Lwr)	10mg (Upr), -10mg (Lwr)
242 - 262	252	3.82% (Upr)" , -4.13% (Lwr)	10mg (Upr), -10mg (Lwr)
263 - 283	273	3.53% (Upr)" , -3.80% (Lwr)	10mg (Upr), -10mg (Lwr)
284 - 314	294	6.37% (Upr)" , -3.52% (Lwr)	20mg (Upr), -10mg (Lwr)
315 - 346	336	2.89% (Upr)" , -6.67% (Lwr)	10mg (Upr), -21mg (Lwr)
347 - 367	357	2.72% (Upr)" , -2.88% (Lwr)	10mg (Upr), -10mg (Lwr)
368 - 388	378	2.58% (Upr)" , -2.72% (Lwr)	10mg (Upr), -10mg (Lwr)
389 - 419	399	4.77% (Upr)" , -2.57% (Lwr)	20mg (Upr), -10mg (Lwr)
420 - 461	441	4.34% (Upr)" , -5.00% (Lwr)	20mg (Upr), -21mg (Lwr)
462 - 514	483	6.03% (Upr)" , -4.55% (Lwr)	31mg (Upr), -21mg (Lwr)
515 - 566	546	3.53% (Upr)" , -6.02% (Lwr)	20mg (Upr), -31mg (Lwr)
567 - 618	588	4.85% (Upr)" , -3.70% (Lwr)	30mg (Upr), -21mg (Lwr)
619 - 683	651	4.69% (Upr)" , -5.17% (Lwr)	32mg (Upr), -32mg (Lwr)
684 - 755	714	5.43% (Upr)" , -4.39% (Lwr)	41mg (Upr), -30mg (Lwr)
756 - 839	798	4.89% (Upr)" , -5.56% (Lwr)	41mg (Upr), -42mg (Lwr)
840 - 933	882	5.47% (Upr)" , -5.00% (Lwr)	51mg (Upr), -42mg (Lwr)
934 - 1040	987	5.10% (Upr)" , -5.67% (Lwr)	53mg (Upr), -53mg (Lwr)

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		

## DOSE BANDING TABLES – ORAL ANTI-CANCER MEDICATIONS:

### CAPECITABINE (Version 2)

The dose bands used in this table are constructed based on combinations of 500mg, 300mg and 150mg capecitabine tablets

Dose rounding has been applied to this table in order to facilitate the nearest measurable combination of tablets available.

Dose Range (mg)	Banded Dose (mg)	Maximum variation range (%)	Maximum variation range (mg)	Suggested Tablets needed:
750 - 850	<b>800</b>	5.88% (Upr)" , -5.88% (Lwr)	50mg (Upr), -50mg (Lwr)	1x500mg and 1x300mg
851 - 950	<b>900</b>	5.26% (Upr)" , -5.16% (Lwr)	50mg (Upr), -49mg (Lwr)	3x300mg
951 - 1075	<b>1000</b>	6.98% (Upr)" , -4.56% (Lwr)	75mg (Upr), -49mg (Lwr)	2x500mg
1075 - 1200	<b>1150</b>	4.17% (Upr)" , -6.25% (Lwr)	50mg (Upr), -75mg (Lwr)	2x500mg and 1x150mg
1201 - 1375	<b>1300</b>	5.45% (Upr)" , -7.20% (Lwr)	75mg (Upr), -99mg (Lwr)	2x500mg and 1x300mg
1376 - 1475	<b>1450</b>	1.69% (Upr)" , -5.02% (Lwr)	25mg (Upr), -74mg (Lwr)	2x500mg, 3x150mg
1476 - 1550	<b>1500</b>	3.23% (Upr)" , -1.55% (Lwr)	50mg (Upr), -24mg (Lwr)	3x500mg
1551 - 1700	<b>1600</b>	5.88% (Upr)" , -2.88% (Lwr)	100mg (Upr), -49mg (Lwr)	2x500mg and 2x300mg
1701 - 1900	<b>1800</b>	5.26% (Upr)" , -5.21% (Lwr)	100mg (Upr), -99mg (Lwr)	3x500mg and 1x300mg
1901 - 2075	<b>2000</b>	3.61% (Upr)" , -4.77% (Lwr)	75mg (Upr), -99mg (Lwr)	4x500mg
2076 - 2225	<b>2150</b>	3.37% (Upr)" , -3.33% (Lwr)	75mg (Upr), -74mg (Lwr)	4x500mg and 1x150mg
2226 - 2400	<b>2300</b>	4.17% (Upr)" , -3.08% (Lwr)	100mg (Upr), -74mg (Lwr)	4x500mg, 1x 300mg
2401 - 2575	<b>2500</b>	2.91% (Upr)" , -3.84% (Lwr)	75mg (Upr), -99mg (Lwr)	5x500mg
2576 - 2775	<b>2650</b>	4.50% (Upr)" , -2.67% (Lwr)	125mg (Upr), -74mg (Lwr)	5x500mg and 1x150mg
2776 - 2900	<b>2800</b>	3.45% (Upr)" , -0.83% (Lwr)	100mg (Upr), -24mg (Lwr)	5x500mg, 1x300mg

NCCP Dose Banding Tables	Published: 23/08/2019 Review: 23/08/2021	Version: 4
This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/nccpdosebanding">www.hse.ie/nccpdosebanding</a>		